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Editor's Note: We Are Providing You the Health Policy Newsletter
To keep Bulletin readers informed about Jefferson, while containing mail
costs, another publication is being shipped with the Bulletin. We believe
you'll find that the Health Policy Newsletter tells you about topics that
supplement those in the Bulletin. The Health Policy Newsletter is shipped
quarterly, and describes health policy questions that Jefferson is studying.
Please let us know your thoughts by directing them to
Attention: Editor, Alumni Bulletin
Jefferson Medical College
1020 Locust M-41
Phila., PA 19107
Phone: 215 955 7920
Fax: 215 923 9916
Email: Malcolm.Clendenin@maiLtju.edu
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Can You Share Your Jeff Experience 4
with a Potential Student in Your Area?
There may be students in your geographic region who have been admitted
to Jefferson Medical College, but are still in the process of deciding whether to

Upcoming Events
December 10, Friday at 8 P.M.
Free public concert by Thomas Jefferson University Choir and Orchestra
Conducted by Robert Sataloff '75
First Baptist Church, 17th and Sansom Streets
January 11, Tuesday
Alumni reception with Paul C. Brucker, M.D., President of
Thomas Jefferson University, in San Diego
January 12, Wednesday
Alumni reception with Dr. Brucker in Los Angeles
January 14, Friday
Alumni reception with Dr. Brucker in Honolulu
January 19, Wednesday
Alumni reception for first year students, in Jefferson Alumni Hall
January 20-28
Cruise to the Canary Islands with Jeff alumni

attend Jefferson or another medical school. Benjamin Bacharach '56, Associate
Dean for Alumni Relations and Acting Executive Director of the Alumni
Association, urges you to talk with them about your Jefferson experience.

January 27, Thursday
Alumni Executive Committee meeting

The Alumni Office will put you in touch with specific students. Simply fill out
the form below and return it to JMC Alumni Office, 1020 Locust Street M-41,
Philadelphia, PA 19107.

February 5-12
CME and Ski meeting, Telluride, Colorado
March 10, Friday
Parents Day for sophomores

Name

Class Year or Jeff Affiliation
March 16, Thursday
Jefferson Center for Integrative Medicine event with Andrew Weil, M.D.
in Philadelphia

Mailing Address

City

State

Zip

Alumni Executive Committee meeting

Daytime Phone

I would be willing to talk with students who are deciding whether to attend Jefferson.

Can You Host a Student Interviewing
or Doing a Rotation in Your Area?
Students will be contacting alumni during November, December, and January
requesting housing while they are interviewing for residencies. They may be
calling at other times of the year when they are doing a clinical rotation at a
hospital in your area (as part of their third and fourth years of medical school).
Alumni have found that this is a fun way to catch up on what's happening at Jeff,
and to meet physicians-to-be who may eventually be practicing in their region.
If you would be willing to host a Jefferson student, please return the form below
to JMC Alumni Office, 1020 Locust Street M-41, Philadelphia, PA 19107.

Name

March 23, Thursday

Class Year or Jeff Affiliation

April 15, Saturday
TJUH Women's Board Jefferson Ball in Philadelphia
April 27, Thursday
Alumni annual business meeting
May 15, Monday
Alumni reception with Dean and Senior Vice President for Academic Affairs
Joseph S. Gonnella, M.D., at the Stanford Inn, Palo Alto, CA
May 16, Tuesday
Alumni reception with Dr. Gonnella in Sacramento, CA
May 17, Wednesday
Alumni reception with Dr. Gonnella in San Francisco
May 18, Thursday
Alumni reception with Dr. Gonnella in Denver
Reunion Weekend 2000

Mailing Address

June 9, Friday, alumni banquet
June 10, Saturday, clinic presentations, reunion parties
City

State

Zip

Daytime Phone
I would be willing to host a student interviewing or doing a rotation in my area
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Bringing Cancer Knowledge from the
A s we embark on the 21st century, Thomas Jefferson University is deploying
'..imaginative research and treatment against a disease that strikes one of
every four Americans. Jefferson's Kimmel Cancer Center is not a single building
but an integration of components, including the Bluemle Life Sciences Building,
Bodine Center for Cancer Treatment, and oncology programs within various
departments. Scientists and clinicians are coordinated through an infrastructure
that can promote common goals and centralize data management, expediting
the transfer of research results to the bedside of the sick.
Cancer research at Jefferson took a major step forward at the beginning of this
decade with the recruitment of Carlo Croce, M.D., a world renowned geneticist.
He oversees laboratories, primarily in the Bluemle Building, that encompass
molecular biology, biochemistry, cell biology, immunology, structural biology,
developmental biology, and genome mapping.
Our efforts got a tremendous boost in 1995 when Sidney Kimmel, founder and
chairman of the Jones Apparel Group, a leading women's clothing manufacturer,
donated $10 million for research and for an endowed fund to continue
Jefferson's fight against cancer. In appreciation, the university renamed its
programs the Kimmel Cancer Institute and Kimmel Cancer Center.
Also in 1995, Jefferson achieved recognition by the National Cancer Institute as
a Clinical Cancer Center, one of five in Pennsylvania and approximately 60
nationwide.
The Kimmel Cancer Institute consistently merits grants approaching $50
million annually, roughly three-quarters from the National Institutes of Health
and the NCI, and the rest from nonfederal grants. This extramural funding
makes cancer the largest research program at Jefferson.

lymphoma. TCL-1 is one of a group of genes implicated in the proliferation of
T-cells and B-cells. Cancer occurs when the TLC-1 gene is moved out of its
normal sequence on chromosome 14, and placed next to other elements known
as enhancers which cause the gene to produce too much of its protein product.
TCL-1 is the first gene to be implicated in low-grade leukemias such as T-cell
prolymphocytic leukemia, T-cell chronic lymphocytic leukemia, and adult Tcell leukemia.
Recently, Jefferson investigators led by Dr. Croce and Professor Kay Huebner,
Ph.D. discovered the FHIT gene, the second largest gene yet identified, which is
involved in many common cancers (see page 13). Much work remains to be
done before its mechanisms are clarified, but its significance is so great that the
National Cancer Institute has called the discovery of the FHIT gene "the Rosetta
Stone of cancer research."

Clinical Research
Clinical cancer research at Jefferson is approaching the same level of excellence
as our basic scientists. Walter Curran, M.D., Chair of Radiation Oncology at
Jefferson, undertook the additional responsibility of Clinical Director of the
Kimmel Cancer Center in 1997. He also serves as co-director of the lung cancer
and brain tumor programs, and helped develop the Neurosensory Institute at
Jefferson and Wills Eye Hospital which specializes in the use of the Gamma
Knife and stereotactic radiosurgery, a super-precise radiation therapy. On the
national level, Curran chairs the Radiation Therapy Oncology Group, a federally
supported coalition of university departments which cooperate on clinical trials
(the RTOG was in fact founded at Jefferson in the late 1960s by Dr. Simon
Kramer).
A newly formed Translational Research Committee at
the Kimmel Cancer Center promotes collaboration
between Jefferson's basic and clinical scientists, and

Unraveling Genetic Mechanisms
The investigations at the Kimmel Cancer Institute (see pages 13-15) center
around oncogenes which arise in the normal genome, sometimes as a result of
certain viruses. Oncogenes up-regulate cell division. If they are mutated or
translocated to another site, cells may divide out of control, causing cancer.
A contributing factor can be mutations in tumor suppressor genes, which
dampen the ability of cells to divide. If tumor suppressor genes mutate or are
translocated, the body's normal controls against cancerous growth can be lost.

Capizzi

With 10 million cells dividing in the normal human body every minute, and the
external environment impacting upon the body, genetic mutations inevitably
occur and are passed on. Humans also have genes which can repair DNA
damage. But if these repair genes themselves become mutated, DNA errors may
go uncorrected. This increases the chance that tumors will develop as the body
is exposed to carcinogenic substances that alter DNA (see page 15, lower right).

Boman

An early accomplishment by Jefferson's cancer researchers was the identification
of a gene that plays a crucial role in promoting types of leukemia and
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ensures that they meet all the steps required in
federally funded projects. Multidisciplinary teams
cross department lines to focus on such areas as
hematologic malignancies and lung, genitourinary,
gastrointestinal, and head and neck cancers. Jefferson
is a national leader for treatment of leukemia and
colorectal cancer in particular.
Robert Capizzi, M.D., the Magee Chair of the
Department of Medicine, has reorganized its Division
of Medical Oncology and Medical Genetics to reflect
increased interest in cancer genetics. Bruce Boman,
M.D., Ph.D., an expert on hereditary cancer
syndromes, particularly hereditary nonpolyposis colon
cancer and familial adenomatous polyposis, was
recruited to head this division. Services include family
pedigree analysis, individual risk assessment, genetic
counseling, and genetic testing.

4i

Laboratory to the Patient
Cancer Network and
Oncology Group
Jefferson is active in national coalitions conducting clinical trials,
such as the Eastern Cooperative Oncology Group, the Gynecologic
Oncologic Group, the Radiation Therapy Oncology Group, and the
National Surgical Adjuvant Breast and Bowel Project. The number
of cancer trials at Jefferson is increasing very rapidly.
Many of the institutions linked together in the Jefferson Health
System have formed the Jefferson Cancer Network (JCN) to
enhance clinical and translational research by increasing the number
of individuals enrolled in these trials. Patients at any JCN member
can easily become enrolled in a wide array of trials, which offer
patients the latest therapies as soon as they have been developed.
Currently the network includes Jefferson, Atlantic City Medical
Center, Bryn Mawr Hospital, duPont Hospital for Children, Albert
Einstein Medical Center, Frankford Hospital, Grand View Hospital,
Lankenau Hospital, Mercy Community Hospital, Mercy Fitzgerald
Hospital, Mercy Hospital of Philadelphia, Methodist Hospital,
Riddle Memorial Hospital, Underwood-Memorial Hospital, Wills
Eye Hospital, and the Kimmel Cancer Center radiation oncology
programs at Chestnut Hill and Lower Bucks Hospitals.

Curran in the radiation facility
With approximately 20,000 new cancer patients diagnosed within the
Jefferson Cancer Network each year, Dr. Capizzi believes the Kimmel
Center now has the critical mass needed to run conclusive clinical trials
within the JCN itself. The Kimmel Center and the network provide
sufficient infrastructure, technology, and numbers of patients to be a selfcontained trials group—the Jefferson Oncology Group—along the lines of
the Eastern Cooperative Oncology Group.
The JOG now has a common Institutional Review Board with approval
authority over all trials involving its members. And the member institutions are being coordinated so as to have a single signature contracting
ability with pharmaceutical industry sponsors.
Back on the university's Center City campus, it is likely that in the year
2002, many of the scientists and clinicians of the Kimmel Cancer Center
will move into a large new structure of their own. It would include
outpatient facilities for ambulatory cancer patients, as well as research labs.
The clinical side of the building would be laid out so as to encourage
interaction between clinicians and investigators dealing with the same
types of pathology.
The new cancer building would mean a major expansion of total lab space,
enabling Jefferson to recruit more investigators and obtain significantly
more federal grant money than at present. Jefferson will become even more

Radiation therapists prepare a patient.
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Increasing the Effectiveness of Radi(
N

early two thirds of people diagnosed with cancer today will receive
radiation as part of their therapy. Incremental improvements in
technology over the last century have culminated in what Chair of Radiation
Oncology Walter J. Curran Jr., M.D. calls "revolutionary improvements over the
last decade." At Jefferson's Kimmel Cancer Center, that revolution can be seen at
the 50,000 square foot Bodine Center for Cancer Treatment, opened 12 years
ago not only to offer the best, but also to ensure the continual development of
new radiation therapy technologies.
What has changed in recent years, said Curran, is that
radiation oncologists and other cancer specialists have
learned that the best cancer treatment often incorporates
multiple specialties and modalities. "With trained oncology
nurses, with pharmacists, with psychologists and social
workers, the Bodine Center was one of the first centers in the
Philadelphia area to recognize the need for multispecialty
collaboration in the management of cancer patients," said
Curran. "And we still serve as a model of that." Radiotherapy
may be used in conjunction with surgery or chemotherapy to
achieve more complete tumor elimination or to control
metastasis, and in some cases it can also be used in place of
surgery when the goal is to preserve organ function, such as
in the case of cancers of the throat, larynx, esophagus,
prostate, and breast.

a number of different directions. "That works rather well in concentrating the
radiation in the target area and sparing the critical
structures," said James M. Galvin, D.Sc., Professor and
Director of the Medical Physics Division in the Department
of Radiation Oncology. "We use our bag of tricks to get a
good dose distribution." These tricks include various
techniques that weight the fields differently and modify them

An alternative to the traditional approach to treatment
planning, called inverse planning, is now being used at
Jefferson. Employing a delivery system called "Peacock,"
which was developed by Nomos Corporation of Sewickley,
Pennsylvania, it allows the radiation oncologist to start with
what is the ideal dose distribution and to work backward

Curran

icant benefit to patients with cancers that are locally advanced or that have
spread to the bone or the brain. Said Curran, "Probably about half of patients
who have incurable cancer benefit from radiotherapy in terms of quality of life
and pain control."
The approach that Jefferson uses incorporates different technologies to provide
image-based treatment planning and delivery. That typically includes techniques
that immobilize the patient to the greatest degree possible; imaging modalities
such as spiral CT scanning, which provides high resolution images; and
planning tools that calculate the most effective way to deliver the right dose of
ionizing radiation to the target while sparing normal tissues.

Precision Targeting
For the more than 200,000 men each year diagnosed with prostate cancer, all of
the treatment options have risks. Surgery, while offering the potential of
complete removal of the tumor, too often results in damage to the surrounding
nerves, sometimes resulting in impotence and incontinence. Radiotherapy, in
contrast, offers an increased likelihood of retaining sexual potency. Yet irradiating prostate tumors buried deep in the pelvis places nearby sensitive
structures such as the rectum and bladder at risk of radiation-induced damage.
In order for radiation therapy to be an acceptable alternative in prostate cancer
and many other forms of cancer, techniques have been developed that concen-

JEFFERSON

The traditional approach to treatment planning, called conformal 3-D treatment,
is to look at the cross-sectional CT image of the tumor and arrange the fields to
miss healthy structures as much as possible, and then to irradiate the tumor from.

with absorbers placed in the beam.

And even when a cure is not the goal, palliative radiotherapy may provide signif-
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trate the delivery of ionizing radiation to the tumor itself, while limiting radiation
exposure of the surrounding tissue.
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' from that point to determine the appropriate configuration of
radiation delivery. "It's a total reversal of the approach," said
Curran. "Normally we think of the fields and base the dose
strictly on that. Here we think of the dose and then use the treatment planning
technology to determine the delivery process that will give us that dose."
The Peacock system delivers what is called intensity modulated radiation therapy
(IMRT), using an approach known as "layered therapy," said Maria WernerWasik, M.D., Assistant Professor of Radiation Oncology. A special crane moves
across the treatment table, delivering many small radiation beams of varying
intensity. This allows the physician to modify the delivery of radiation to
conform to the shape of the tumor, even if it is an irregular shape, and to get
uniform levels of radiation to tumors that vary in thickness and that have hardto-reach margins, while at the same time avoiding normal tissue. "It's the
radiation oncologist's dream to be able to do this," said Werner-Wasik. By
delivering radiation more precisely, Peacock allows the physician to deliver
higher levels of radiation without harming normal tissue, thus increasing the
likelihood of cure.
In addition, physicians may be able to provide a second course of radiotherapy
when necessary. "Peacock may allow us in some cases to treat tumors that recur
after initial courses of radiation," said Werner-Wasik.
The key to inverse planning is computation, according to Galvin. "You give the
computer very detailed geometric information about the tumor you're trying to
treat, and also about the critical body structures in the vicinity," he said. "Then
you ask the computer to determine the ideal combination of beams and angles
that will deliver a homogeneous dose of radiation to the various areas of the
tumor regardless of its shape. And you give the computer the flexibility of
varying the beam intensity at will."

December 1999

terapies
The idea of inverse planning was developed in the 1980s and '90s, before there
were convenient ways available for modulating the beam intensity point for
point. "It was a technique in search of a technology to implement it," said
Galvin. But in the early '90s, he and others introduced a new field-shaping
device called the multi-leaf collimator, with which one can obtain any irregularly shaped field using a computer to drive fingers in and out of the radiation
beam. "It occurred to me that if you shaped different fields and then stacked
them up, you could build up any intensity pattern. So with the introduction of
the multi-leaf collimator, we now had a tool to modulate the intensity of the
beam so we could deliver these inverse plans."
This allowed radiation treatments to be shaped to irregular tumor volumes. "We
could now shape the dose to a horseshoe-shaped tumor with a critical structure
right in the center of it. We couldn't do that in the past."
The problem with inverse planning is that the computer sometimes comes up
with very elaborate solutions: elegant dose distributions that are difficult to
deliver because of various compromises that were called for during the planning
process. For example, when the tumor surrounds a critical structure, the
delivery of sophisticated distributions of radiation sometimes requires
sacrificing dose homogeneity.

CT or MRI scan. Historically, patients simply lay on a table while receiving
radiation therapy. Then, plastic molds were introduced which kept people
from rolling around during treatment. "But if you want to give high doses of
radiation to critical areas in the body, we've concluded that you really need to
have more rigid immobilization," said Curran. Jefferson was one of the first
American sites to use the stereotactic body frame to immobilize patients during
radiation therapy, and remains the only one in the Delaware Valley.
The device looks barbaric, Curran remarks, resembling the kind of box a
magician uses when he cuts a woman in half. The patient is placed in it prior
to a CT scan. Images produced from this scan show the location of the tumor
relative to fixed points in space provided by the calibrating device. Then,
while the patient's positioning is maintained by the box, he is moved to the
treatment area where radiation is delivered relative to those same fixed
calibration points.
The difficulty comes in transferring the patient from the CT scanner to the
treatment area. Jefferson staff, however, have developed a unique transferring
technique in which the patient can be moved off the CT scanner, down the
hall, and into the treatment unit without being jostled.
The Jefferson team uses a modified hospital gurney to facilitate this transfer.

"So here at Jefferson we asked, well, if we're going to change the rules of
treatment planning so dramatically, then why not go back to the traditional
techniques and see how they perform under this new set of rules," said Galvin.
This has led to the development of a new approach, dubbed forward planning as
opposed to inverse planning. "We still have made it an intensity modulated
delivery, it's just that whereas we had inverse planning coupled with IMRT,
we're now using traditional techniques combined with IMRT. We have fields
within fields and we still stack fields, but we use our past experience to say what
those fields within fields should look like." While optimization of the plan is
still left to the computer, said Galvin, "We give the computer
more information going in, and tell the computer that we
think that these fields are the ones it should be looking at.
`Now, computer, you optimize it.' "

The gurney allows the staff to slide the patient smoothly off the CT couch,
onto the transfer couch, and then onto the treatment table. Then, using marks
on the patient and on the frame, the radiation fields are delivered to an exact
position within the patient's body.
"The importance of doing this is that we can now decrease the margins,"
Galvin explained. Margins refer to the area surrounding the tumor that may be
irradiated during the treatment. Less precise localization of the tumor or more
uncertainty about the patient's exact position relative to the images means that
those margins must be increased in order to ensure
adequate delivery of radiation to the tumor. "We're trying
to minimize the size of the margins so that we are
irradiating less of the healthy tissue, while still getting all
of the tumor."

Galvin explained that while inverse planning may be the
wave of the future, the forward planning technique being
developed at Jefferson is more suited to the technology that
is currently available. Eventually, there may be a melding of

New Approaches Make
Radiotherapy Better

the two approaches, he said. "The terminology will
change—it will become simply computerized planning."

Holding Still
Galvin
Another device that maximizes delivery of radiation to the
target and not to surrounding tissue is the stereotactic body frame (see front
cover photo), a piece of equipment with calibrating devices built into it that
allow the precise localization of body structures in three dimensions during a
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For all of these new technologies, rigorous evaluation of
the results is the key to ensuring progress in the search for
better treatments. Jefferson patients benefit from participation in clinical trials of protocols developed all over the
world, due to the university's involvement in federally
funded cooperative oncology groups such as the Radiation
Therapy Oncology Group, which Curran currently chairs. These clinical trials
are essential for the continued evolution of therapies that will yield better
outcomes and fewer side effects.

December 1999

biochemically quite different from those of radiation and
Dr. Dicker explains

drugs, Leeper explained. First, heat denaturizes proteins,

a set of CT scans.

in the same way that when you cook an egg, the protein in
the white changes from a clear, slippery liquid to a white

Right: Dr. Leeper

solid mass. By denaturing and changing the structure of
proteins in cells, heat inhibits the repair of the tumor's
damage from radiation and chemotherapeutic agents.

Below: A radiation
For example, clinical trials recently resulted in

therapist prepares a

preliminary FDA approval for an agent called

patient for treatment.

tumor's DNA more reactive with drugs and radiation, increasing the effectiveness

amifostine, which protects against radiation-induced

The mask protects

of the drugs and radiation. And what makes the combination of heat and radio-

dry mouth, or xerostomia. Werner-Wasik with

areas of the face.

or chemotherapy even more desirable, is that the cells in tumors that are sensitive

Second, through other chemical and biochemical processes, heat makes the

Robert Capizzi, M.D., the Magee
Chair of the Department of
Medicine, conducted this trial at
Jefferson, and Werner-Wasik
continues to see if this agent might
be useful as a protectant against
chemo- and radiation-induced
esophagitis in lung cancer patients.
Adam Dicker, M.D., Ph.D, Assistant
Professor of Radiation Oncology,
meanwhile has been working with a
technique called brachytherapy, in
which radioactive seeds are
implanted into early stage prostate
tumors. Dicker collaborates with
Professor Frank M. Waterman,
Ph.D. The idea behind
brachytherapy is that higher doses
of radiation can be delivered directly
to the tumor, without affecting
adjacent tissues. Long term studies
of the effectiveness of brachytherapy
are underway, as is research to
improve the methodology.
Werner-Wasik discusses a procedure, along with visiting fellow Marisa LoBao, M.D.

Adjuvant Therapies
Many of the most promising developments in radiation oncology involve the use
of adjunctive therapies that augment the standard treatment. One that has
undergone extensive development at Jefferson is hyperthermia, or applying heat
to the tumor. In the past two decades, said Dennis Leeper, Ph.D., Professor of
Radiation Oncology, about 700 patients have received hyperthermia treatments
at Jefferson.
Hyperthermia increases the effectiveness of radiation therapy through two
pathways: by killing cells directly and by making cells more sensitive to
radiation-induced damage. The mechanisms of hyperthermia's effects are
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RADIATION ONCOLOGY RESEARCH
Women with Inherited Breast Cancer Gene
Are at Greater Risk for Recurrence and New Tumors
Li or many women under 40 with

breast cancer, surgery to remove
the lump and accompanying radiation
seem a good way to get rid of the
disease yet preserve the natural
breast. But for women who carry a
damaged version of BRCA1 or
BRCA2, genes predisposing them to
breast cancer, such treatment may not
be enough. Researchers at Jefferson
have found that such women have a
greater risk of either relapsing or
developing new tumors years later
than those women who receive a
lumpectomy and radiation therapy
but don't carry one of these genes.
As a result, says Bruce Turner, M.D.,
Ph.D., Assistant Professor of
Radiation Oncology, who led the
work, women and physicians may
want to rethink their treatment
options. "Our findings suggest that a
woman who has a mutation in
BRCA1 or BRCA2 who is treated with
breast-conserving therapy not only
has a high risk of local
recurrence-40 percent according to
our study—but also a high risk of
developing cancer in the other breast
as well," Dr. Turner says.
"Our data imply that breastconserving therapy may not be the
optimal treatment for breast cancer
patients with BRCA1 or BRCA2
mutations who want to reduce the
risk of locally recurrent breast
cancer."
Dr. Turner and colleagues at Yale
University and Myriad Genetics
reported their findings in the October
issue of the Journal of Clinical
Oncology.
Of 170,000 new breast cancer cases a
year in U.S. women, about 10 percent

to
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of the women are under 40. Roughly
10 to 15 percent of those women
(2,000) carry an altered BRCA1 or
BRCA2 gene, and about 70 to 80
percent develop breast cancer.
Dr. Turner and his
coworkers looked at the
frequency of alterations in
BRCA1 and BRCA2 in 52
breast cancer patients who,
between 1973 and 1994,
were treated with breastconserving lumpectomy
Turner
and radiation, and who
subsequently developed a recurrent
cancer in the same breast. They
compared these women to 52 other
women who had localized breast
cancer and were treated similarly but
did not experience recurrent disease.
The researchers found that eight, or
15 percent, of the 52 women who had
further breast cancer also carried a
damaged BRCA1 or BRCA2 gene. In
women 40 or under with recurrent
breast cancer, six of 15, or 40 percent,
had a damaged inherited BRCA1 or
BRCA2 gene. In contrast, only one of
15 women in the comparison group
who did not have any recurrent
cancers carried the bad gene.
The scientists also found that it took
longer—an average of about eight
years—for women with an altered
BRCA1 or BRCA2 gene to relapse
than it did women without the
damaged gene (slightly less than five
years on average). They then carefully
examined the tumors using molecular
and histologic analysis, thinking these
were old cancers that had returned.
Instead, they found that some of the
tumors were actually completely new
breast cancers. The new cancers took
an average of 8.5 years to develop.

Medical College Alumni Bulletin

Radiation and Prostate, from page 9

"If this study is validated with a larger
prospective study, it may suggest that
BRCA1 or BRCA2 testing may be
reasonable to determine optimal
breast cancer treatment—either
breast-conserving therapy,
or mastectomy for younger
women with family
histories of breast or
ovarian cancer," Dr.
Turner says.
The study results may
present women and their
physicians with some
difficult decisions regarding
treatments. "If you told a woman with
a damaged BRCA1 or BRCA2 gene
that in nine years, 40 to 50 percent of
patients like her are going to have a
new breast cancer, and may need a
mastectomy, then you'd have to
present alternatives to her: would she
prefer the lumpectomy and seven
weeks of radiation, or would she
rather have the mastectomy now and
reduce the risk of recurrent disease?"
One problem with recurring cancer is
the threat that the disease may spread.
While breast-conserving therapy may
be curative for many women, some
women who develop recurrent breast
cancer also develop metastatic disease.
Dr. Turner says that researchers now
need to "look at patients with BRCA1
or BRCA2 who have had a
mastectomy and consider the
frequency of chest-wall relapse and
metastatic disease.
"Presumably, removing 90 to 95
percent of the breast cancer cells by
mastectomy significantly reduces the
future risk of breast cancer. But more
definitive data is needed before we can
justify this recommendation."

it
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Prostate cancer tends to be a slow
growing disease that men
frequently die with, not from.
Doctors often question whether
surgery or radiation provide any
real benefit for the older patient.
Since 1990, the reported new cases
of prostate cancer have more than
tripled, from fewer than 100,000
annually to more than 300,000,
owing to better detection and
greater public awareness. More
than 60,000 men a year receive
radiation therapy for localized
disease.
Dr. Valicenti and his Jefferson
colleagues followed 149 men with
localized cancer that had not
spread beyond the prostate, who
were considered high-risk for
cancer recurrence after surgery.
Fifty-two men were given radiation
therapy three to six months after
surgery; the others received no
radiation.
The scientists carefully matched
the two groups according to factors
that predict whether a cancer will
return, settling on 72 patients in 36
matched pairs. They then examined
the patients every three to six
months and tested their blood for
prostate-specific antigen. Rising
PSA indicates a returning cancer.
After five years, 89 percent of the
matched patients who had received
radiation after surgery had no
detectable PSA level, compared to
only 55 percent of those who didn't
get radiation.
Valicenti and his colleagues hope
to conduct a multisite national
study to see if these results can be
repeated with a larger group. 111.

Clinical Trial of Radiation and
Thalidomide for Brain Tumors

R

esearchers at Jefferson and 14
Cher sites around the country
are enrolling patients into a National

While surgery and radiation are the
standard treatments for
glioblastoma, their effects are

Cancer Institute sponsored clinical
trial examining the effects of radiation
and thalidomide in treating
glioblastoma multiforme, a deadly
brain cancer. The Phase Two trial,
conducted by the nationwide clinical
trial cooperative known as the
Radiation Therapy Oncology Group,

usually temporary. Chemotherapy
has marginal value, failing to reach
areas in the brain to which the
cancer has spread, says Curran,
"which is why we have looked for
alternatives." The study will include

in collaboration with Celgene
Corporation of Warren, New Jersey,

chemotherapy.

aims to determine the drug's safety
and effectiveness in extending
patients' lives. The study, which will
last into the year 2000, involves
approximately 80 patients.

Thalidomide works by cutting off
the blood supply to tumors. Tumor
cells are frequently able to engineer
new vessel growth, a process
called angiogenesis (see graphic on
page 9), which promotes the
cancer's spread. Thalidomide
inhibits a growth factor that tumor
cells need in order to sprout new
vessels. Thalidomide won't knock
out the cancer cells, but may prevent
them from spreading by cutting off
nutrients which they need in order
to multiply. Because the drug targets

Glioblastoma multiforme is the
deadliest type of brain tumor.
Although any of the brain's cells can
turn malignant, glioblastoma
multiforme, a tumor of the glial cells,
is the most common and the most
malignant. The tumor has a tendency
to infiltrate surrounding tissue and is
commonly associated with promoting
blood vessel growth, bleeding, and
tissue death. In the United States, the
disease strikes approximately 9,000
individuals, with a median survival
time of about 12 months following
diagnosis.
"This combination treatment may be
an important step in fighting a
normally intractable illness that
resists all other therapies," says
Walter J. Curran Jr., M.D., Chair of
the Radiation Therapy Oncology
Group and Clinical Director of
Jefferson's Kimmel Cancer Center.
Curran points out that the RTOG
study "is the first trial of its kind to
look at radiation and thalidomide in
treating any cancer."
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patients who have not previously
undergone radiation therapy or

rapidly dividing cells, it is not
expected to cut off the blood supply
to most normal cells.

Adjuvant Therapies, from page 9
to grow, they require new blood vessels to deliver oxygen and nutrients. By
blocking the formation of new vessels, researchers believe they may be able to
starve the tumor. Since angiogenesis inhibitors are cytostatic (preventing the
growth of a tumor) rather than cytotoxic (killing the tumor), they will most
likely be used in conjunction with chemotherapy or radiation therapy as a
cancer treatment.
One of the anti-angiogenesis agents being tested at Jefferson is thalidomide,
the same drug that was widely given, with disastrous results, to pregnant
women in the 1950s as a treatment for morning sickness. Thalidomide was
withdrawn from the market when it was shown to cause severe birth defects.
But in 1994, researchers demonstrated that the very properties that damaged
the developing fetus, that is, inhibition of new vessel growth, could be used
therapeutically to starve tissues such as tumors. An RTOG-sponsored clinical
trial of thalidomide used in conjunction with radiotherapy as a treatment for
brain glioma is now underway (see article at left), with Jefferson's Adam
Dicker chairing the correlative studies section of the trial.
icker explained that angiogenesis, as measured by the density of
Dmicrovessels (the MVD) in a given area, has been shown in many
studies to correlate with tumor extent, aggressiveness, decreased survival, and
lymph node metastases. A landmark paper in 1991 showed that in a study of
women with breast cancer, all patients with microvessel counts over a certain
threshold developed metastases. "This was the precedent for thinking, well, if
there's increased angiogenesis in patients with more advanced disease, then
presumably if you impact on the angiogenesis you might impact on the overall
progression of the disease," said Dicker, who is collaborating on research with
George Iliakis, Ph.D., Professor and Director of the Radiobiology Division.
Another reason for the excitement about angiogenesis inhibitors is that
preclinical data indicates little likelihood that tumors will develop resistance
to these agents. "It takes a long time for these anti-angiogenesis agents to have
an effect," Dicker notes, "but they have a very durable length of response."

If thalidomide works, it would be a
complement to other strategies like
surgery, chemotherapy, and
radiation. "To control brain tumors
effectively, we need a whole host of
services," Curran explains.
In the 1960s, thalidomide, originally
intended to treat morning sickness,
was banned around the world after
causing thousands of babies to be
born either without limbs or with
flipper-like arms and legs. In recent
years, however, the drug has been
used to treat leprosy, cancer, AIDS,

While Curran and the faculty in Radiation Oncology are proud of the basic,
translational, and clinical research programs, Curran stresses that patient care
is the top priority. To this end, the Kimmel Cancer Center recently celebrated
the addition of two new partners, the radiation oncology center at Frankford
Hospital, and the Jefferson radiation oncology center at Riddle Memorial
Hospital in Delaware County. These facilities will help increase the number of
newly referred patients seen through the Jefferson system to about 3,500 per
year. Many of these patients are seen in multidisciplinary programs and
benefit from the collaborations of researchers and clinicians in multiple
specialties.
"We're devoted to offering state of the art therapy while at the same time
critically evaluating its potential benefit to patients," said Curran. "Just
because it's new technology doesn't mean it's better." —Lisa J. Bain

and other diseases.
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Continuing Recognition for Jefferson's Specialists
efferson's many experts on the
causes and treatment of cancer
continue to earn national recognition.
A few highlights this past year:

isolated and named the ALL-1 gene,
which is critical to the development
of leukemias and lymphomas. Dr.
Croce and Dr. Kay Huebner identified

AACR-Pezcoller Award for
Cancer Research

and cloned the tumor suppressor
gene FHIT, which continues to yield
vital information on the development
of cancer (see article on facing page).

Celebrated
geneticist Carlo
M. Croce, M.D.,
Director of
Jefferson's
Kimmel Cancer
Center, has
added the
AACR-Pezcoller Award to his long list
of achievements. The award is given
by the American Association for
Cancer Research to a scientist who
has made a major discovery in cancer
research.
Dr. Croce, who also chairs Jefferson's
Department of Microbiology and
Immunology, has been a pioneer in
understanding the genetic causes of
cancer. The AACR noted that his
"contributions have not only greatly
extended our knowledge of cancer
genetics, but they also constitute the
basis for potential breakthroughs in
gene therapy for human cancer."
Among his accomplishments, Dr.
Croce has explained the roles of
chromosome alterations in human
leukemias and lymphomas and
identified several genes involved in
blood cancers. A genetic profile of
these genes is already being used in
clinical settings to detect remaining
disease in patients following
treatment.
More specifically, Croce described the
molecular-genetic events that result
in Burkitt's lymphoma, follicular
lymphoma, and lymphomas in AIDS
patients. He and his team have also
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A member of the National Academy
of Sciences, Croce has won numerous
honors including two Outstanding
Investigator Awards from the
National Cancer Institute, the
General Motors Research Foundation
Charles S. Mott Prize, the Pasarow
Award, and the John Scott Award.
Nation's Top Cancer Specialists
According to Good Housekeeping
Jefferson faculty Walter J. Curran Jr.,
M.D., Robert D. Fry, M.D., and
Gordon Schwartz, M.D. are among
the nation's top 318 cancer specialists
for women, according to the 1999
study by Good Housekeeping
magazine. The guide lists the most
respected experts for lung, breast, and
colon disease.
Good Housekeeping's editors made
their selections based on nominations
from nearly 300 department chairs
and section chiefs at major medical
centers around the United States.
These physicians were asked to select
"the specialists who provide the most
expert treatment and who are the
leading clinicians for lung, breast, and
colon cancer in women."
As Clinical Director of Jefferson's
Kimmel Cancer Center, Dr. Curran
oversees a range of the most advanced
patient services in every specialty
dealing with cancer. The Kimmel
Center also acts as the point of entry
for patients taking part in clinical
trials conducted by Jefferson cancer
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specialists. Curran is also Chair of
Radiation Oncology at Jefferson, and
heads the Radiation Therapy
Oncology Group, a consortium of
more than 200 institutions in the U.S.
and Canada aligned to conduct
clinical trials.

treatment for this type of early breast
cancer. DCIS currently represents 20
to 25 percent of all breast cancers
diagnosed.

Robert Fry,
M.D.,
Director of
Colon and
Rectal Surgery
at Jefferson,
has written
extensively on

Stephen Feig, M.D.,

the care of gastrointestinal disorders
and cancers, especially those affecting
the colon and rectum. He has collaborated on more than 20 books and
book chapters. Dr. Fry continues
Jefferson's unparalleled success in
managing colorectal cancer, and is
also pursuing studies of the
mechanism and treatment of inflammatory bowel disease. He is a
Director of both the American Board
of Colon and Rectal Surgery and the
American Board of Surgery.
Gordon F. Schwartz, M.D., Professor
of Surgery at Jefferson, is a worldrenowned breast cancer surgeon. He
serves on the editorial boards of
Cancer, Seminars in Breast Disease,
The Breast Journal, International
Journal of the Breast, and Mammary
Pathology, and is a member of the
National Institutes of Health
Reviewers Reserve.
Dr. Schwartz also heads an international group of breast cancer experts
who meet at Jefferson each year to
discuss the diagnosis and treatment of
Ductal Carcinoma in Situ (DCIS), a
controversial malignancy found in the
breast. In recent years, the group
designed a system for classifying
DCIS, a first step toward improving
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President of the
Society of Breast Imaging

Professor of
Radiology at Jefferson and Director
of the Breast Imaging
Center, is now the
national President of
the Society of Breast
Imaging. A nationally recognized
radiologist who specializes in breast
cancer detection and diagnosis, Dr.
Feig was one of the founding
members of SBI in 1985. The society
comprises more than 2,000
radiologists.
Feig is the author or coauthor of
more than 300 papers and chapters
and 15 books on breast imaging and
breast cancer detection. His research
has covered benefits, risks, and costs
of screening mammography,
especially for women ages 40 to 49,
the technical quality of mammography, and digital mammography.
Dr. Feig is also a member of the
American College of Radiology Breast
Task Force and chairs the ACR's
Mammography Accreditation
Committee and the Ad Hoc
Committee on Mammography
Screening Guidelines. He holds
leadership positions in the National
Council on Radiation Protection and
Measurements and the American
Board of Radiology. He is Editor of
the journal Seminars in Breast Disease
and serves on the editorial board of
Radiology.'

'

GENETIC EC ANISMS
Molecular Pathways of Apoptosis

gone awry underlies cancer, neurode-

explains. "We wanted to know which

generative diseases such as

amino acids were involved."

T y detailing the precise molecular

cellular events leading to activation of

Alzheimer's and Parkinson's, and

„ pathways of apoptosis, or

this enzyme in apoptosis.

autoimmune diseases such as lupus.

The scientists overexpressed and

"Labs across the country are trying to

Apoptosis has received great attention

and caspase-9 that bind to each other.

programmed cell death, scientists at
Jefferson are edging closer to new

crystallized the actual pieces of Apaf-1

therapies against cancer, Alzheimer's

develop drugs that inhibit caspases, in

in the popular press in recent years

Then they used x-ray crystallography

disease, and Parkinson's disease.

order to fight neurodegenerative

since scientists discovered that part of

to analyze the chemical structure of

diseases and other diseases in which

the reason cancer cells grow with

the recognition complex. They showed

In the June 10 issue of the journal

apoptosis is involved," points out Dr.

abandon is that they lose the directive

how mutation of even a single critical

Nature, Emad Alnemri, Ph.D.,

Alnemri. Understanding the apoptotic

to die at a preset time.

amino acid within the recognition

Associate Professor of Microbiology

pathway and each protein's role in the

and Immunology at Jefferson, in

cell-to-cell communication process

Alnemri is studying how various

between the two proteins.

complex can affect the binding

collaboration with Yigong Shi, Ph.D.

will open the way to developing

molecules affect the process, particu-

of Princeton University, described the

drugs.

larly what triggers it to begin with. He

workings of caspase-9, an enzyme

Dr. Alnemri contends that a key to

focuses on caspases, a family of 14

halting the disease processes involved

that is crucial to apoptosis. They have

Apoptosis is a fundamental biological

proteases (enzymes that degrade

in degenerative diseases such as

elucidated part of the cascade of

process that is vital to cell differenti-

critical cellular proteins). Seven of

Alzheimer's may lie in this attachment.

ation and normal

these are known to be involved in

"If we find a molecule that can disrupt

development. In

apoptosis. Alnemri and his coworkers

these two proteins from binding, it

human embryos,

discovered many of the caspases

could be used in a drug. For example,

for example,

themselves.

a compound that could bind to the

apoptosis creates

surface of the caspase might block the

fingers from

In the Nature paper, the researchers

apoptotic pathway and prevent the

mitt-like hands.

concentrated on better understanding

process from occurring."

It occurs during

the chemical "recognition complex,"

normal aging,

or precise binding region, between

Creating such drugs would involve

and sometimes

caspase-9 and Apaf-1 (apoptotic

developing peptides that mimic the
chemical "recognition sequence" on

during

protease activating factor one), a

irreversible cell

protein that helps regulate apoptosis.

the two crystal structures of caspase-9

injury from

"They bind to each other—we

and Apaf-1, and then testing to see if

radiation or

published that in an earlier journal

they indeed disrupt apoptosis. It

other poisons.

article—but no one knew how. The

would be a first: no caspase-based

Scientists believe

crystal structure of the binding

drugs currently exist that block

that apoptosis

complex was unclear," Alnemri

apoptosis in this manner.

Further Evidence Links FHIT Damage with Breast Cancer
Immunology at Jefferson, showed

and a reduced expression of the Fhit

L./with the University Hospital of

reduced levels of Fhit, the protein for

protein.

cientists at Jefferson, working
Iceland and the National Human

which FHIT encodes, both in women

Genome Research Institute in

with sporadic breast cancer and in

"Genetic alterations at this most

Bethesda, Maryland, have found

those with hereditary breast cancer

common fragile site in the FHIT gene

further evidence linking damage to

who carry a BRCA2 mutation, a gene

lead to reduced Fhit protein expression

the tumor suppressor gene FHIT to

predisposing them to develop the

in sporadic cancers and in a much

the development of breast cancer.

disease. Among the 58 sporadic and

larger fraction of BRCA2-associated

34 BRCA2-associated breast cancers,

familial cancer," Dr. Huebner explains.

In a study of 92 Icelandic women,

Dr. Huebner's team reported a "signif-

"This is consistent with the idea that

researchers led by Kay Huebner,

icant association" between damage to

loss of BRCA2 function affects the

Ph.D., Professor of Microbiology and

the FHIT gene at its most fragile area

stability of the FHIT site."
continued on page 15
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UNRAVELING MOLECULAR MECHANI
Structural Approaches to New Therapies:
Jefferson Symposium Attracts Some of the Foremost Experts
diverse group of scientists
eeting this past spring at
Jefferson demonstrated the power and
the potential of structural biology and
chemistry in the search for novel
therapies. The symposium,
"Structural Chemistry and Biology of
Cancer and Immune Diseases: From
Basic Research to the Clinic," was
organized by Ziwei Huang, Ph.D.,
Director of Rational Drug Design at
Jefferson's Kimmel Cancer Institute.
It attracted scientists from both
academia and industry and from
disciplines ranging across the
spectrum of basic and clinical science.
What all these scientists shared was a
research approach that exploits
knowledge about the molecular
structure of various proteins: using
these structures as templates in the
design of molecules that interfere
with or regulate the function of
physiological systems. But these
scientists' specific tactics and targets
varied. Targets include cancer cells
and viruses as well as the molecules
involved in cell cycle regulation,
immunomodulation, and
angiogenesis.
Some of the new therapies developed
using this structural approach have
already made it to the clinic, and
many more are in the pipeline.

Structural Variations Yield
Different Activity Profiles
One approach with implications in
the fight against both cancer and viral
diseases such as HIV involves the use
of molecules that are structurally
similar to the nucleotides normally
used as building blocks in DNA
synthesis. Dr. Yung-Chi Cheng,
Professor of Pharmacology at Yale
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University, described a new class of
these agents called L-nucleoside
analogs, which take advantage of the
unique features of DNA synthesis in
cancer cells or virally infected cells.
Currently there are several deoxynucleoside analogs, such as AZT
(zidovudine) and ddC (zalatibine),
which are used clinically against HIV.
When these compounds get into the
cells of individuals infected with HIV,
they are chemically altered and then
incorporated preferentially into the
viral DNA, where they prevent
interaction with the viral enzyme
reverse transcriptase so that the DNA
chain can no longer elongate, and
DNA synthesis stops. While these
compounds do interfere with viral
reproduction without causing bone
marrow suppression (an acute toxic
reaction associated with other antiviral agents), prolonged clinical use of
these drugs has resulted in a delayed
type of toxicity affecting various
tissues and organ systems.
Dr. Cheng's lab was interested in
studying the underlying mechanism
of the delayed toxicity. They
discovered that it was due to a
depletion of mitochondrial rather
than nuclear DNA, and that even
slight differences in the structure of
the deoxynucleosides resulted in
different toxicity profiles. At the same
time, his lab was searching for
compounds that would be effective
against the hepatitis B virus (HBV).
Dr. Cheng reasoned that since HBV
uses a reverse transcriptase similar to
HIV, the nucleotide analogs effective
against HIV might also work against
HBV. Indeed, they found that antiHIV compounds such as ddC were
effective against HBV. They went on
to synthesize compounds with a
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number of structural variations and
found that different modifications
yielded compounds effective against
different viruses as well as
compounds that interfered with the
reproduction of some cancer cells.
Further, the knowledge that they are
gaining about the effect of these
compounds on viral infections has
yielded new insight about the role of
molecular structure in the
phenomena of drug resistance and
synergism when combinations of
drugs are used.

Modulating Immunity
Structurally
While Dr. Cheng searched specifically
for compounds that might interfere
with the virus itself, other scientists
have sought means of stimulating the
immune system to defend more
effectively against viral diseases and
cancer. Dr. Harvey Cantor, Professor
of Pathology at Harvard Medical
School, discussed an anti-cancer
vaccine strategy that seeks to
modulate the cytokines that mediate
protective immune responses.
According to Dr. Cantor, the current
paradigm for cytokine interaction is
that interleukin-12 (IL-12), produced
by macrophages and dendritic cells,
imprints a Type I or cell mediated
immune response. Another cytokine,
IL-10, diminishes the Type I response
while encouraging the humoral or
allergic (Type II) response. Dr.
Cantor's lab has been studying a gene
called Eta-1 (for Early T-cell
Activation), which is the major newly
synthesized RNA in activated T-cells.
"We think that the expression of Eta1 is an essential early link between
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T-cell activation on the one hand and
the drive towards Type I immunity on
the other; and that the engagement of
its two receptors, leading to
diminished IL-10 and increased IL12, is the key to its action," he said.
According to Dr. Cantor, the two
effects of Eta-1 are mediated by
distinct receptors that interact with
different portions of the Eta-1
molecule. When one end of the
molecule, the N-terminus, is
phosphorylated, it engages one type
of receptor and leads to IL-12 upregulation. The other end of the
molecule, the C-terminus, engages a
different receptor and down-regulates
IL-10.
By understanding the role that
chemical structure plays in these
regulatory mechanisms, Cantor hopes
to be able to engineer structural
modifications that will allow manipulation of this part of the immune
response. "This kind of observation
also opens possibilities for using this
cytokine or engineered versions of
these cytokines in vaccines," he said.

Interfering with Receptor
Binding and Activation
Dr. Elias Lolis, Associate Professor of
Pharmacology at Yale, discussed a
subset of cytokines called
chemokines, chemotactic cytokines
that mediate inflammation.
Chemokines comprise the largest
family of cytokines, with over 40
distinct types identified. They play a
role in immune defense,
hematopoiesis, and angiogenesis.
Chemokines interact with receptors
expressed on subgroups of
leukocytes, white blood cells that
mediate the inflammatory response.

Receptor activation initiates a cascade
of biochemical reactions that regulate
intracellular processes. Chemokine
receptors also may bind to pathogens
and this binding may be a
requirement for the organism to enter
the cell. The understanding of this
function for chemokine receptors
recently led several groups of
scientists to the discovery that some
individuals who appear resistant to
HIV infection in fact have a mutation
in the chemokine receptor dubbed
CCR5. This mutation prevents the
CCR5 molecule from reaching the
cell surface; as a result HIV cannot
bind and gain entry to the cell. Since
these individuals appear to be
otherwise healthy, CCR5 may be a
safe target for inhibition.
Dr. Lolis has been working to define,
at a structural and chemical level, the
process of chemokine binding and
receptor activation with the goal of
designing safe and effective
inhibitors. Because the chemokines
are important in so many physiologic
systems, compounds that modulate
chemokine activity could have
applications in treating a broad range
of illnesses.
Structural biologists and chemists
have targeted numerous other
receptor/ligand binding interactions
with the goal of manipulating the cell
cycle. Wayne Hendrickson, Professor
of Biochemistry and Molecular
Biology at Columbia, discussed one of
the most ubiquitous of these
processes: signalling by cellular
growth factors through receptor
tyrosine kinases. Through different
but related pathways, protein tyrosine
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kinases mediate the process by which
a variety of growth factors and
hormones exert their effects. "Many
different pathways work through
tyrosine kinases," Hendrickson said.
"What's emerging is a nicely unified
set of principles by which these
actions occur."
Protein kinases transmit signals along
various pathways by transferring
phosphate groups to other proteins.
The structural changes that result
from phosphorylation may result in a
gain or loss of function in that
protein. One important type of
protein kinases is called the cyclindependent kinases (CDKs).
"You can think of the CDKs as
engines that drive the cell cycle,
whose regulation is frequently altered
in neoplasia," said Dr. Edward A.
Sausville of the National Cancer
Institute. Consequently, he said,
"They represent a potential target for
both refining prognosis and defining
new therapies." In fact, the NCI is
currently involved in Phase I clinical
trials of a direct CDK antagonist
called flavopiridol. According to
Sausville, flavopiridol appears to act
at two different phases of the cell
cycle. In addition, different types of
tumors are differentially sensitive to
flavopiridol-induced apoptosis
(programmed cell death), indicating
that the full story of how the drug
works may be more complicated than
CDK antagonism—as well as more
revealing about the function of the
CDKs.
These are only a sampling of the
approaches discussed at the Jefferson
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symposium, yet representative of the
types of strategies structural
biologists and chemists are using to
understand disease processes and
develop new therapies. Combined
with techniques developed by

FHIT,

Jefferson's Dr. Huang for computer
design of molecules, these structural
approaches promise significant
advances in the battle against cancer,
AIDS, and many other diseases of
our time. —Lisa J. Bain

from page 13

An improved understanding of the
FHIT gene may lead to the identification of individuals predisposed to
some of the most common human
cancers, and the development of new
drugs that may arrest their growth.
In 1996, Dr. Huebner and Carlo M.
Croce, M.D., Director of Jefferson's
Kimmel Cancer Center, identified and
characterized FHIT. It is located in
the human genome's most fragile
area, on human chromosome three in
a region known as 3p14.2. The area
has an exceptionally high number of
DNA gaps, breaks, and rearrangements. The researchers believe that
FHIT's fragility is involved in the start
or progression of such cancers as
esophageal, gastric, kidney, breast,
and lung.
"We knew that this region on
chromosome three was prone to
damage by carcinogens," Dr. Huebner
says, "though we don't know what
those carcinogens are, or what causes
the genetic breakage. In sporadic
tumors, the FHIT site is damaged,
and the BRCA2 gene, and maybe
BRCA1, are active and can probably
repair the damage.
"But when BRCA2 is missing, many
cells cannot repair the damage
without BRCA2's repair mechanism;
and this contributes to cancer growth.
Perhaps part of what BRCA2 does is

December 1999

to protect the integrity of the cell,
especially in fragile regions. BRCA2
function appears to be important to
the stability of the FHIT site.
"One of the reasons this is exciting is
because of what it tells us about
repair genes in general in cancer,"
Professor Huebner says. It is possible
that FHIT and the fragile
chromosome three site are also more
likely to be severely damaged in
tumors of people with MSH2 and
MLH1, such as in colorectal cancers.
Previous studies of patients from
Iceland showed a loss of DNA that
was significantly higher in this region
in familial compared to sporadic
tumors. In this study, tumors in more
than 30 women with hereditary breast
cancer showed variously lower
amounts of Fhit. All of the women
had a defective BRCA2 gene predisposing them to cancer. Dr. Huebner's
researchers think that the frequency
of women with a damaged FHIT in
cancer cells could indicate that those
with a missing BRCA2 can't repair
DNA damage when it occurs in FHIT.
"Currently, we are looking at other
fragile sites in BRCA2 and BRCA1
cases and in MLH1 and MSH2associated tumors, which are deficient
in DNA repair mechanisms. It would
be very helpful to know which genes
are affected when you lose BRCA2
repair function."

Proof that Access to New Methods
of Prevention Depends on
Where Patients Receive Care
ow well are medical advances
translated into community practice?

treat special medical complications. "If a woman was treated at
one of these sites, she was more
likely to be treated with antiretroviral therapy," Turner says.

(2) were being treated at sites paid by
the state to deliver a range of specific

"Similarly, if a woman was

In the case of HIV-infected pregnant

HIV-focused services to persons

treated at a site that had earlier

women, where they get their care may

enrolled on Medicaid, (3) were

been part of the 076 trial, she was

receiving prenatal care, or (4) were in a

50 to 70 percent more likely to

make a big difference.

methadone program.

receive antiretroviral therapy.

In 1994, researchers across the country

That argues for care from medical

were thrilled when they found that the
anti-HIV drug AZT, taken during the

"Where women get their medical care
makes a big difference in whether they

second and third trimester, could reduce

get access to important advances," says

mother-newborn transmission of AIDS by

Barbara J. Turner, M.D., Professor of

as much as two-thirds. Along with

Medicine and Director of Health Care

national educational efforts, New York

Research at Jefferson's Center for

State mounted an information campaign,

Research in Medical Education and

sending letters to physicians and other

Health Care, who led the study. The

health care specialists, even conducting

findings were reported June 15 in the

marketing campaigns to high-risk groups.

Annals of Internal Medicine.

Researchers at Jefferson asked, how
quickly would community practitioners

The study involved the results of the
Pediatric AIDS Clinical Trials Group

(who are statistically slow to change their

protocol 076, arguably the biggest

approaches) adopt new practices to treat

advance in HIV prevention yet. The trial

poor, pregnant, HIV-infected patients?
Which patients would benefit from the

was halted early and its results showed

new knowledge?

AIDS transmission could be substantially reduced during delivery by giving
AZT to the pregnant women during the

While community physicians in New

last two trimesters of pregnancy, and to

York State responded rapidly to the

the baby during the first six months of

findings, patients in certain health care

life. But because the findings were not

settings benefited much more than

published for nine months, Dr. Turner

others. The researchers found that

explains, "the news got out via news

women were more likely to receive

releases, educational programs for lay

antiretroviral treatment during pregnancy
if they were (1) being treated at a medical

persons and professionals, and direct
mailings to doctors" (rather than via a

center that performed HIV clinical trials,

definitive peer reviewed journal article).

centers that offer clinical trials."
Dr. Turner sees several lessons
Turner
In the Annals paper, Dr. Turner and her

from her team's study, which was
funded by the National Institute on

January 1993 until the announcement;

Drug Abuse, including the possible
need for a "direct marketing program

nine months from announcement until

after a dramatic finding such as the 067

colleagues examined three time periods:

formal journal publication; and after

trial. The adoption of medical advances

formal publication until September 1996.

in private practice has been statistically

They looked at the treatment records of

far slower than in academic medical

2,607 HIV-infected women who delivered
live children. They found that after

centers."

adjusting for patient and health care
delivery factors, these Medicaid enrolled

Currently, Dr. Turner and her
coworkers are following the data on the

women had a 21 percent increase per
month in their likelihood of receiving

women through 1998 to see which
groups of women received antiretroviral

antiretroviral therapy during pregnancy.

therapy up to two years after they gave

After the formal journal publication, the

birth.

rate increased more slowly.
In recognition of her expertise on health
"But we found that certain women were

care practices, Dr. Turner has recently

more likely to be treated," says Dr. Turner, been appointed Medical Editor of
Hippocrates, a journal for primary care
physicians published by the

such as those already receiving care at
centers of excellence. New York State has
identified centers and physicians who
contract to deliver a range of HIV-related
services (such as nutritional care) and to

Massachusetts Medical Society
(publisher of the New England Journal of
Medicine)

0.1

A Mechanism to Control Red Blood Cell and Platelet Production
esearchers at Jefferson have
uncovered a potential switch that
helps control the manufacture of red
blood cells and blood-clotting platelets.
By better understanding how the body
keeps tight reins on this process, the

circulating red blood cells. Athletes may
artificially boost the number of red
blood cells (as many Olympic officials
know) using a hormone, erythropoietin, which helps immature red
blood cells to mature. But too many

scientists hope to someday therapeuti-

cells can cause sluggish circulation and

cally control blood cell production.

stroke.

For our tissues to have the oxygen they

Controlling the amount of the hormone
is one way of regulating red blood cell

crave, we need to have enough

production. But there's another way,
called "negative regulation," which
involves blocking the growth and differentiation of red cell precursors. By
activating the cell's own programmed

Jefferson, Ruggero De Maria, M.D., and
their coworkers at Jefferson and the
Istituto Superiore di Sanita in Rome,
found evidence that by activating so-

suicide process, apoptosis, researchers

called "death receptors" on the surface
of immature red blood cells, an

can halt the excessive production of red
blood cells.

important protein called GATA-1 can
be turned off. GATA-1 is crucial to the

Cesare Peschle, M.D., Professor of

development of immature blood cells.
The team reported its work September

Microbiology and Immunology at

30 in the journal Nature.
continued on page 18
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Despite the Best Available Drugs, HIV Is Indeed Active in the Bloodstream
were halted, all patients' viruses returned

Until now. Roger J. Pomerantz, M.D.,

eradication." Dr. Pomerantz also calls for
better detection methods, because "in the

to earlier levels, and they developed

found evidence for the first time of

Chief of Infectious Diseases, and his
coworkers examined 22 HIV-infected

era of HAART, we're often dealing with

symptoms.

low levels of virus."

rrhe best AIDS drugs are still not good
enough. Scientists at Jefferson have
actively replicating HIV in the

patients taking HAART. Using ultrasen-

bloodstream of patients taking the most

sitive molecular techniques, he and his

powerful anti-HIV drugs available.

team found evidence of active virus in
the blood plasma of every patient. Their

Scientists knew that the combination of
drugs known as HAART, highly active

results appear November 3 in the Journal
of the American Medical Association.

latent form in the semen of infected men
taking HAART, even when no measurable

of blood plasma. Using extremely
sensitive techniques, Pomerantz's team

patients: residual HIV that's replicating,

found active virus in every person.

He's using these new findings in ongoing

"We need to be able to stop replication

A recent study of patients on HAART and

clinical studies to attempt to eradicate
HIV in certain patients.

of the virus before we think about

interleukin-2 showed that when the drugs

virus could not be detected by conven-

patients, the virus spills out of the
immune cells it normally infects, and
spills into the blood, possibly infecting
other cells," says Pomerantz.

one had been able to find active virus in
the blood of patients on the drugs.

still present in a potentially infectious,

virus can be found in the blood. "Now

"We are the first to show that in such

arrested the virus from replicating. No

transcriptase inhibitors, who had no
available clinical assays. All patients had
fewer than 50 copies of virus per milliliter

the AIDS virus, despite the fact that the

they thought that the drugs had at least

people taking HAART, a combination
therapy of protease and reverse

in the seminal fluid of 10 patients. They
previously reported that the AIDS virus is

detectable virus in their blood by the best

antiretroviral therapy, did not eradicate

tional means in the patient's blood. But

Pomerantz's group also found active virus
Pomerantz's JAMA article looked at

we're dealing with two things in these
and residual HIV that's latent," he says.

Drug Profiles and Tailor-made Therapies Are Needed
clinically.

"Two things need to be done,"
Pomerantz says. "We need to

patients you are this much resistant to

IV resistance to drugs by creating
drug resistance profiles of patients

Y, and not to these others."

before they begin treatment, writes

In the JAMA editorial, Pomerantz

understand how large the problem of
primary drug resistance is, and part of

Roger J. Pomerantz, M.D. in the

comments on two studies published in

that means watching different

Dr. Pomerantz sees the day when each

September 22 issue of the Journal of the
American Medical Association. By

that issue that focus on groups of
patients in quite different geographic

geographic areas to gauge how much
multidrug resistance is developing.

anti-HIV drug will actually have a
profile of standard viral resistance. "You

knowing which drugs a patient is
resistant to, doctors may someday

locations. Some of the patients in both

Then, for each drug, we have to find a

could say to a patient, 'This is your

studies were resistant to a commonly

way to agree on what the degree of

virus, these are the drugs it's resistant

prescribed and frequently effective

clinically relevant resistance is.

to, and this is what we'll use against it.'"
Tailor-made, individually designed

"Clinically relevant drug resistance will

therapies may become more common.

esearchers may be able to sidestep

custom-design therapies against HIV,
and thereby improve treatment.

viral resistance means something

cocktail of drugs known as highly active
antiretroviral therapy (HAART).

drug X and that much resistant to drug

differ for each drug, just as it is different

But certain obstacles still stand in the
way, explains Dr. Pomerantz, who is

The researchers in both studies defined

for penicillin and vancomycin for

Chief of Infectious Diseases at Jeff.

drug resistance differently, leading to

bacteria," he says. "We have to find out

Dr. Pomerantz compares the current
AIDS drug resistance situation to the

More research is needed to understand

different opinions about the degree of

if a threefold increase in viral resistance

drug resistance, and scientists must

resistance found in the study popula-

means something about the effectiveness

early days of bacteriology at the turn of
the century. Doctors watched how new

come to agreement on when a patient's

tions.

of one drug compared to what it means

drugs affected different patients, and

for another," he says.

devised new definitions of clinically
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In the JAMA editorial, he calls for
medical officials to be more alert to
multidrug resistance. "If you give a
patient a cocktail of drugs the first time
and they don't respond, and you can't
find it's from noncompliance, you have

relevant conditions. "HIV is evolving
differently in different areas of the
country," he says. "Defining resistance
for each drug is exactly what we did
earlier in the century for bacterial
infections such as tuberculosis, when
people were developing resistance."

to think they may have primary
resistance."

Of course, detailing the precise viral
genetic makeup of each HIV-infected

Eventually, all patients may need to be

individual would cause treatment costs

profiled for both their virus's genetic

to rise significantly. This would be a

makeup and their disease status, "just as

particular problem for Third World

we do for pneumococcus and tubercu-

nations struggling against the onslaught

losis before treatment," he says.

of AIDS. Millions are infected, and
many lack primary medical care. No

"What does it mean when you have X
resistance to AZT, and at the same time,

one knows the scope of drug resistance
there, Dr. Pomerantz points out,

drug, such as a certain protease

because in many cases, patients do not
receive adequate medical attention, let

inhibitor? It would be desirable to tell

alone consistent therapy.

what does it mean regarding a different

INVESTIGATIONS
Jefferson Discovery of How to Isolate Stem Cells
Could Lead to Lab Production of Blood Cells
dentists at Jefferson have found a

S

way to isolate hematopoietic stem
cells. "This has been the elusive Holy
Grail of hematology and
immunology," says Cesare Peschle,
M.D., Professor of Microbiology and
Immunology. "Now we have found it,
by identifying the first specific and
functional stem cell marker."
This could lead to laboratory
production of all types of blood cells,
for transfusions and for innovative
approaches to bone marrow
transplants and gene therapy.
Dr. Peschle (who is also Chair of
Hematology-oncology at Istituto
Superiore di Sanita in Rome) and his
coworkers at Jefferson's Kimmel
Cancer Center, and in Italy, Germany,
and at the University of Nevada
reported their work September 3 in the
journal Science.
Hematopoietic stem cells, created by
bone marrow, have two unique
abilities: to develop into any kind of
blood cell and to self-renew by
generating new daughter stem cells.
Yet they are very rare, making up only
one in 100,000 marrow cells. They
have been notoriously difficult to
distinguish from the blood's other
progenitor cells, which are further
along in the differentiation process.
"We have found a marker—KDRwhich seems to be specific for the
hematopoietic stem cell as compared
to other primitive hematopoietic
cells," Dr. Peschle says.
"The use of the stem cell is very
important and broad. Having purified
it, we can characterize it at a
functional, phenotypic, and molecular
level." Scientists can also learn to
manipulate the cell in the laboratory,
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he says, and "to induce the stem cell
to do in the laboratory what it does in
the body: self-renew and differentiate
to generate a huge number of red
blood cells, white blood cells, and
platelets." Scientists then can generate
in the lab the circulating blood cells
required for blood transfusions, which
currently are obtained by transfusions
from normal donors.
For years, researchers have had
tremendous difficulty distinguishing
between two types of precursor blood
cells: hematopoietic progenitor and
stem cells. Progenitor cells are
immature cells that can differentiate
into red blood cells, white blood cells,
and platelets. They are used to restore
patients' blood and immune systems
after high dose chemotherapy or
radiation for cancer. Stem cells are
earlier cells which have the unique
capacity to self-perpetuate. They
generate progenitor cells and blood
cells throughout life. Progenitors have
no self-renewal capacity—they only
give rise to more differentiated
precursor cells.
Scientists can isolate undifferentiated
progenitor cells using a marker on the
cell known as CD34. This methodology was pioneered by Dr. Peschle
and coworkers in a report in Science
in 1990. But identifying hematopoietic
stem cells has been more difficult,
Peschle explains. Hematopoietic
progenitor cells are rare: between 0.5
and one percent of bone marrow cells
are progenitors carrying CD34. Yet
stem cells are even less frequent,
perhaps 0.1 percent of CD34 cells, or
one stem cell in 100,000 marrow cells.
The problem was that there was no
specific marker on the cell surface of
stem cells comparable to CD34 on
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progenitor cells. "Once you have a
marker protein for hematopoietic
stem cells," Dr. Peschle explains,
"you can theoretically raise antibodies
against the marker, and then you can
separate stem cells from other cell
populations."
They focused on KDR, a protein that
functions as a receptor for the
vascular endothelial growth factor.
KDR is expressed on endothelial cells.
The scientists found that it is also
expressed at low levels on CD34positive progenitor cells. In
embryonic life, primitive
hematopoietic cells are made in
close contact with KDR-positive
endothelial cells. They argued that
KDR may represent a marker for
hematopoietic stem cells after birth.
They found an antibody that
recognized the KDR receptor and
which could isolate the KDRexpressing cells from the other
progenitors in the CD34-positive
progenitor population. Those cells
with KDR comprised the
hematopoietic stem cells but no
progenitor cells.
Now Dr. Peschle and his coworkers
have precisely evaluated the
capability of KDR-positive stem cells
to repopulate the bone marrow with
blood cells after marrow transplants
in animals. They can also determine
the exact frequency of stem cells in
the KDR-positive population.
The ability to eventually harness the
hematopoietic stem cell in both the
laboratory and clinic should help
alleviate blood shortages for transfusions, and permit innovative
approaches to marrow
transplants.
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Red Blood Cells, from page 16
The team found that turning on
immature red blood cell death receptors
triggers caspases, a family of 14 cysteine
enzymes that degrade critical cellular
proteins, such as GATA-1. This
culminates in a reversible blockade of
growth and differentiation of red cell
precursors, which may lead to cell
death. Their article in Nature details
part of the intricate cascade of cellular
events leading to activation of these
enzymes in the blockade of red blood
cell development.
Apoptosis is a fundamental biological
process that is vital to cell differentiation and normal development. In
human embryos, for example, apoptosis
creates fingers from mitt-like hands. It
occurs during normal aging and
sometimes during irreversible cell injury
from radiation and other poisons.
Scientists believe apoptosis gone awry
underlies neurodegenerative diseases
such as Alzheimer's and Parkinson's
diseases, autoimmune diseases such as
lupus, and cancer.
Apoptosis received a great deal of
attention in recent years when scientists
discovered that part of the reason cancer
cells grow with abandon is that they
lose the ability to die at a preset time.
The Jefferson group's work represents a
"new frontier" in understanding
apoptosis, Dr. Peschle says. He explains
that "mild stimulation of death
receptors and caspases induces a
reversible inhibition of red cell
development rather than apoptosis."
This provides a key mechanism in fine
tuning cell growth and differentiation.
Such a novel mechanism may be of
general significance, he says, and apply
to diverse cell types in addition to red
blood cells and platelets. Failures in the
mechanism may lead to either abnormal
cell growth inhibition or excessive cell
proliferation, such as occurs in some
anemias and leukemias.

Glucosidase Inhibitors May Be Effective against Hepatitis
D esearchers at Jefferson may have

n.found a promising drug against
the hepatitis C virus (HCV). While

they are quick to point out that the
drug, N-nonyl-DNJ, stopped only a
surrogate virus—and not the actual
HCV—from reproducing in the lab,
they believe the findings, which build
on their earlier success against
hepatitis B virus (HBV), may someday
lead to a single drug against both
viruses.
HCV chronically infects some 100
million people worldwide, with as
many as four million chronic carriers
in the United States. Those at risk for
contracting HCV include intravenous
drug abusers, and anyone who had
transfusions prior to 1990, when blood
supply screening for HCV began.
Together, HBV and HCV chronically
infect more than 400 million people.
Approximately one million die each
year from related liver diseases, such
as hepatitis, cirrhosis, and cancer.
Timothy Block, Ph.D., Professor of
Biochemistry and Molecular
Pharmacology at Jefferson, and

colleagues at Oxford University in
England used N-nonyl-DNJ to inhibit
the activity of glucosidase, an
important cellular enzyme. This in
turn prevented the bovine diarrhea
virus, BVDV, which is a tissue culture
model of HCV, from making more
virus. Because HCV cannot be grown
in the lab, researchers use BVDV as a
testing model.
Dr. Block believes glucosidase
inhibitors have a reasonable
likelihood of working against HCV.
"N-nonyl-DNJ is the first drug since
alpha-interferon to my knowledge for
which there is published experimental
evidence against HCV—in the form of
BVDV susceptibility," says Dr. Block.
The drug may sidestep resistant
viruses, the bane of current antihepatitis treatments. "Since the drugs
target a host cellular enzyme at very
nontoxic doses, rather than the virus,
we think that resistance to the drugs
will not be a problem," he says. The
findings appeared October 12 in
Proceedings of the National Academy
of Sciences.

Viruses such as HCV, HBV, and
BVDV reproduce by budding out
from intracellular membranes. The
viruses appear "extremely sensitive to
these drugs, while the normal cellular
processes are not affected," Dr. Block
says. "And because we target this cell
pathway, upon which a whole family
of viruses is dependent, we can
probably develop drugs that have
broad activity" against an array of
viruses.
The next steps are to experimentally
test the drug against HCV and to
determine why the virus is so
sensitive. Potential clinical trials for
the drug are still some time away.
In earlier work, and Dr. Block and his
colleagues at several institutions
found that N-nonyl-DNJ interfered
with a specific step in the life cycle of
the woodchuck hepatitis virus (an
animal model for HBV), essentially
shutting down its ability to infect a
cell. As a result, levels of the virus in
the animals' bloodstream dropped
dramatically.

First Transgenic Mouse Model of Hepatitis B-based Disease

J

efferson faculty have developed the
) first mouse model of chronic liver
disease caused by hepatitis B virus
(HBV), which promises to accelerate
the discovery of drugs against the
disease.
Mark A. Feitelson, Ph.D., Professor of
Pathology, Anatomy, and Cell
Biology, and his colleagues have
developed transgenic mice that are
chronic carriers of HBV. They were
made by introducing the HBV genetic
information into mouse eggs, and
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breeding mice that had viral DNA in
all of their cells. Such mice consistently replicate HBV throughout their
lives. Although other similar models
have been made using normal mice,
none develops chronic liver disease
because the immune system sees the
virus as "self' during embryonic
development.
To solve this problem, Dr. Feitelson
used severe combined immunodeficient mice as viral hosts. These mice
lack critical immune system elements
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that normally would fight the virus.
When the mice are reconstituted with
a normal immune system in a
procedure akin to bone marrow
transplantation, they do not recognize
the virus as "self' and develop liver
disease.
The researchers reported their results
in August in the journal Nature
Medicine.
"The mice see the virus as foreign,
which is what they should do,"
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They found that a very specific step in
the life cycle of the virus can be
selectively inhibited by N-nonyl-DNJ.
The drug worked by inhibiting the
first step in the glycosylation process
that all cell glycoproteins go through
to reproduce. The virus cannot infect
if it doesn't go through this step.
Fortunately, the host cellular
glycoproteins appear to be far less
sensitive to this inhibition than is
HBV, meaning that the animal's own
cells are not badly hurt by the drug.
BVDV and HCV are viruses composed
of RNA, as opposed to HBV, which is
made up of DNA. "They have
different genomes but similar
methods of envelope development:
budding from the endoplasmic
reticulum (ER)," Dr. Block says. "We
think they will all be very sensitive to
N-nonyl-DNJ, since this drug blocks
the first step in ER glycoprocessing
which is needed for some but not all
proteins to fold in the ER." In both
HBV and HCV, the researchers were
able to block the creation of a virus
envelope, locking the virus within the
infected cell. The virus thus was
rendered noninfectious. it

Feitelson explains. This is similar to
the way the human immune system
recognizes HBV shortly after exposure
to the virus.
In addition to chronic liver disease,
these mice have also been manipulated to develop acute disease. "The
differences between acute and
chronic disease in these mice will be
key to the development of new
approaches against the latter,"
Feitelson says, noting that many
individuals with acute disease
recover.
continued on page 23

INVESTIGATIONS
GM1 Ganglioside to Improve Parkinson's Symptoms and Delay Its Advance

S

cientists at Jefferson, armed with
a new $2.4 million grant from the
National Institutes of Health, hope to
find out whether the drug GM1
ganglioside can improve symptoms,

"We hope that we will be able to do
something no one else has done
before: to stimulate remaining brain
cells to sprout new nerve endings and
rescue other cells that might

The Jefferson team is collaborating
with scientists at the University of
Pennsylvania to perform a special
type of imaging called single photon
emission computed tomography, or

Patients with mild to moderate
Parkinson's disease will be divided
into three groups of 50 each. One
group will receive the drug during the
first two study phases. Another 50

delay disease progression, and in
some cases actually restore damaged
brain cells in Parkinson's disease
patients. More than one million
people in the United States suffer

otherwise die," says Dr. Schneider,
who last year published evidence in
the journal Neurology showing that
GM1 may improve symptoms and
perhaps even help slow progression

SPECT. It allows the team to visualize
the number of dopamine terminals in
the striatum, the part of the brain that
receives dopamine from the
substantia nigra (the brain region that

will receive a placebo during phase
one, and the drug during the second
trial phase. A third control group of
50 will receive neither the study
medication nor a placebo, but will

from Parkinson's.

of Parkinson's.

dies in Parkinson's disease).
Comparing patient symptoms and the

receive standard Parkinson's therapy.
This latter group will have the option

Jay S. Schneider, Ph.D., Professor of
Pathology, Cell Biology, and
Anatomy, is leading a five year
clinical trial involving 150 patients. It
will compare the effectiveness of GM1
ganglioside—a naturally occurring
substance in the nerve cell's
membrane that plays a role in cell
growth, development, and repair—to
standard Parkinson's disease
treatments, which improve symptoms
but do not alter the disease process.

"If we can stimulate repair and
regrowth in humans as we've done in
the laboratory, we will have evidence
for the first time of a therapy that can
help restore the part of the nervous
system damaged by a neurodegenerative disease," Dr. Schneider says.

number of dopamine terminals is a
significant advance, Schneider notes.
"This technology will give us insight
into the relationship between the
expression of Parkinsonian
symptoms, and the actual number of
dopamine terminals in the brain."

of receiving the new experimental
medication after the study period
ends.

"Current therapies for Parkinson's
disease treat only the symptoms and
do little to address the underlying
disease. You can alleviate some
symptoms for a time, but the
neurodegeneration continues."

The study is a randomized, double
blind, placebo controlled trial in
which neither the researchers nor the
patients know who receives the drug.

"We're hoping that in the first six
months of the study we'll see the
same kind of symptomatic
improvement we've seen in previous
studies with GM1, as well as a small
increase in the number of dopamine
terminals," Schneider says.

Can Melatonin Help Avoid Parkinson's Damage?

M

elatonin, a substance now
familiar to consumers, could
be a key to understanding how to
treat Parkinson's disease. Scientists at
Jefferson have shown in the
laboratory and in test animals that
melatonin is effective in preventing a
type of brain cell damage similar to
that found in Parkinson's.
It's widely believed that the loss of
dopamine nerve cells seen in
Parkinson's patients' brains, results
from oxidative stress to the cells.
Various cellular insults produce
oxygen free-radicals, resulting in cell
death. The brain's dopamine neurons
are particularly vulnerable.
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Melatonin, a hormone produced by
the brain which is marketed commercially as an anti-aging agent, is the
body's most potent antioxidant. Two
years ago, Professor of Neurology
Lorraine lacovitti, Ph.D. and her
coworkers showed in the laboratory
that melatonin was effective in
blocking the oxidative ravages of
Parkinson's-damaged dopamineproducing cells. They tested the
theory in rats by giving the animals a
toxin, 6-hydroxydopamine, which
specifically damages dopamine
neurons, producing a Parkinsonianlike syndrome. They found that by
injecting melatonin into the rats
either 10 minutes prior to the 6hydroxy infusion, or 30 minutes
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afterward, they could block the
Parkinsonian effects. If they administered melatonin 120 minutes later,
they were able to prevent about half
the damage, or "rescue the cells."
Dr. Iacovitti presented her team's
findings October 24 at the annual
meeting of the Society for
Neuroscience.
In oxidative stress, cells don't automatically die. Rather, they pass through a
cascade of cellular events leading to
cell death. lacovitti and her team used
melatonin to stop the cascade at its
beginning. They plan to explore other
checkpoints in the death cascade to
gauge the compound's effectiveness.
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"If you get enough antioxidants to the
dopamine nerve cells, you might be
able to prevent the kinds of oxidative
stress and cell death you see in
Parkinson's," she believes. Dr.
lacovitti notes that melatonin "has
the correct action to be developed
pharmaceutically," but cautions that
the dosages given to the test animals
were extremely high. "Whether it
could be developed into a safe drug is
another question," she says. "It's
difficult to know at what levels to
keep antioxidants in the body." A
drug company might be able to
isolate an active part of melatonin
that could be a more effective antioxidant at lower doses. it

Stimulating Learning Environment
May Prevent Alzheimer's
A study by a Jefferson scientist
balls, a maze, and a bar-pressing food
n.suggests that a stimulating learning
station. They could choose their food
environment early in life might help
and treats, such as corn chips. Rats
living in standard conditions had no
ward off neurodegenerative diseases
later. Nurture may be more influential
toys and only one food and water
than nature when it comes to the brain's source.
resilience to injury.
Other scientists have shown in recent
Researchers at Jefferson and the
years that brain cell growth and
University of Auckland in New Zealand
replacement can occur throughout
found that rats living in a stimulating
development and aging in animals
environment filled with running wheels, and humans, while brain cell death
tunnels, balls, and food had 45 percent
also occurs. The work by During's
less of the brain cell death commonly
team provides the first compelling
associated with normal development and evidence that a stimulating
aging, than did rats living in basic
environment along with early and
surroundings. What's more, when the
continued learning not only protects
stimulated rats were exposed to a
the brain from disease, but increases
neurotoxin, they suffered almost no loss its capacity to repair and regrow
of brain cells, unlike those in a normal
damaged cells. "We've shown that a
environment. The results were reported
learning environment can encourage
in the April 1999 issue of Nature
cell growth, and also reduce cell
Medicine.
death by about 45 percent (including
both aged cells and young
"We were hoping to find
cells that spontaneously
some scientific underpindie)."
nings to the age-old maxim
'use it or lose it,' " explains
A further step in the
Matthew During, M.D.,
Jefferson study was to give
Director the Central Nervous
both sets of rats kainic
System Gene Therapy Center
acid, a neurotoxin. The
at Jefferson.
brains of rats in the
During
enriched surroundings
Dr. During was surprised how robust the were almost completely protected—a
brains were in rats in a stimulating
dramatic finding.
environment. "We showed in this study
that an enriched environment switched
During and his coworkers are now
on genes in the brain. By this
unraveling the mechanism: the
mechanism, the brain appears to become specific environmental components
resistant to aging, or traumatic brain
and specific interventions that are
injury, or diseases such as Alzheimer's
effective in protecting the brain.
and Parkinson's," he says.
"We're asking whether these genes
we've shown to be active are actually
"There haven't been many proper studies switched on by the environment.
done in the lab to show whether actively What specific genes and chemicals are
using your brain enhances your ability to involved? And can we use them to
stay healthy, and what specific
improve protection of the brain, and
mechanisms might be involved in this.
to treat neurodegenerative diseases?"
We asked what a stimulating
Among the chemicals associated with
environment would do to cognitive
these processes are growth factors,
function, particularly in preventing brain such as glial cell derived neurotrophic
cell death and brain degeneration."
factor and brain derived neurotrophic
factor, and transcription factors.
The enriched learning environment for
rats had running wheels, tunnels, rubber
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Jefferson Ranks in the Top Quarter of
All Medical Schools in Training Grants
11110

efferson Medical College now ranks among the top 25 percent of all
medical schools in the United States in terms of training grants from the
National Institutes of Health.

Of 124 medical colleges receiving NIH training grants, Jefferson is now 30th,
notes Gerald Litwack, Ph.D., Associate Dean for Scientific Affairs. The
ranking is based on an analysis conducted by Dr. Samuel Herman, Jefferson's
liaison to the NIH in Bethesda, Maryland. "Many scientists believe that a
training grant is an indicator of the significance of the research being
conducted," Litwack points out.
In terms of total NIH research dollars, Jefferson is 40th nationally, or within
the top third of all medical schools, Dr. Litwack adds. Amount of NIH
funding is widely seen as an indicator of an institution's quality. "Jefferson is
currently embarked on an organized effort to move up to the top 25 percent
in total NIH dollars," he says.
"For the fiscal year ending June 1999, our research income, including NIH
and all other sources, is estimated at more than $94 million. This is roughly
a $10 million increase over the previous year."
Jefferson currently has about 17 NIH-supported training grants, totaling
more than $2.5 million per year for training. Helping boost Jefferson into the
top 25 percent in this area is a recent $1.2 million award to Jefferson's
Department of Biochemistry and Molecular Pharmacology from the National
Institute of Diabetes, Digestive and Kidney Diseases. The five year grant pays
stipends for four postdoctoral and four predoctoral fellowships in
biomolecular signal transduction. The NIH-funded faculty preceptors come
equally from the Department of Biochemistry and Molecular Pharmacology
and from Jefferson's Kimmel Cancer Institute.
Three of the current NIH training grants are for medical students, for
summer research in cancer and blood and lung disease as well as other areas,
Dr. Litwack adds. "Our success in funding medical students' summer
research outpaces many notable medical schools. Every summer we generate
35 slots for first year medical students who wish to experience research."
These positions are funneled through the Office of Scientific Affairs and
coordinated by Professor Catherine Calkins, Ph.D.
To further increase our funding from the NIH, in order to reach our goal of
the top 25 percent, Litwack says, "Our plans are to increase the size of our
faculty and our research facilities."
It is likely that in the year 2002, many of the researchers and clinicians of the
Kimmel Cancer Center will move into a large new building of their own on
Jefferson's campus. The new structure will mean a major expansion of the
total lab space on campus, enabling Jefferson to recruit many more investigators and obtain significantly more federal grant money, including training
grants, than at present.
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JEFFERSON HEALTH SYSTEM
Senior Health Institute Will Guide Care to the Aging

M

edical progress during the
20th century has dramatically
increased life expectancy. An ever
larger percentage of the population is
over age 65. Many of these
individuals have chronic age-related
conditions such as osteoarthritis,
heart disease, or dementia. Others
have so far remained healthy.
Recognizing their varying needs, the
Jefferson Health System has
developed a Senior Health Institute to
guide its efforts to improve the
quality of life of older persons. The
SHI draws on the expertise of
numerous system members in
research, teaching, and clinical
practice. The objectives are:
1. To foster the development,
quality, and integration of services
for seniors.
The institute has created an inventory
of existing JHS senior health
resources, with a database accessible
via the World Wide Web to increase

awareness of them. Elizabeth White,
M.D., a board certified geriatrician,
has been appointed Medical Director
of Senior Health for the system. She is
organizing the medical directors of
long term care facilities throughout
JHS to develop quality criteria for
physicians, and quality measurement
processes for resident care. Dr. White
is also designing wellness programs
to prevent illness and disability in
assisted-living and continuous care
retirement communities.

Dr. Gitlin is also preparing a
leadership grant application to the
National Institute on Aging. The
research goal is to develop methods
to identify persons at high risk for
disability, and provide them with
services to optimize their health and
prevent health-related crises. This
involves appropriate screening,
utilization of treatment protocols
and clinical guidelines, and coordination of medical and support
services efficiently across multiple

4. To enhance education
in geriatrics.
The directors of training programs
throughout Thomas Jefferson
University and the health system are
developing curricula for medical
students, nurses, occupational
therapists, and physical therapists to
cover such areas as functional
assessment, theories of aging,
expected physiologic changes, the
continuum of long term services, and
the special needs of caregivers.

health care sites.
2. To promote aging research
within JHS.
Laura Gitlin, Ph.D., Director of
Community and Homecare Research
at Thomas Jefferson University's
College of Health Professions, has
compiled an inventory of researchers
in basic science, clinical medicine,
and gerontology to stimulate interdisciplinary and inter-institutional
research. The computerized inventory
will be accessible via the SHI Web
page, to make it easy to search for
investigators across the system.

3. To create "senior friendly"
medical settings.
"Senior sensitive" hospitals and
clinics will have innovative environmental and procedural refinements
to improve hospital experiences for
older patients. The changes will
include early rehabilitation,
minimization of adverse effects of
medications, and formulation of
thoughtful discharge plans.

Market forces have substantially and
perhaps adversely affected medical
practice in this country. For older
adults, misaligned incentives and
fragmented services have perpetuated,
if not exaggerated, the preexisting
deficiencies. We want to tap the
ingenuity and commitment across the
Jefferson Health System to protect
and restore the health of older
persons.
—Barry W. Rovner '80, Medical
Director of the Wills Geriatric
Psychiatry Program, a joint
program of Jefferson and the
Wills Eye Hospital

Lankenau Receives One of Five Grants Nationwide
to Study the Basic Biology of Aging

r

esearchers led by Dr. Vincent J. Cristofalo at
he Lankenau Medical Research Center, a
member of the Jefferson Health System, are the
recipients of a large grant from the National
Institute on Aging for a Nathan Shock Center of
Excellence in the Basic Biology of Aging. This is
one of only five grants in the United States, the
others being at Harvard University, the University
of Michigan, the University of Texas at San
Antonio, and the University of Washington.
The award carries funding over a four-year period
to enhance support facilities for investigations and
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provide a stimulating environment to new
researchers in the field.
Three overlapping and interrelated themes
underlie the program of the Nathan Shock Center:
functional changes in excitable tissues such as
nerve, muscle, and heart, including dementing
diseases such as Alzheimer's disease; changes in
the regulation of gene expression with aging,
including those changes leading to age-associated
diseases such as cancer, atherosclerosis, or
osteoarthritis; and mechanisms of regulation of the
declining function of the immune system.
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The grant currently supports five core resource
units around which the research is structured. The
Animal Core offers properly housed and genetically defined rodents of different ages to qualified
researchers. By providing genetically defined
female rats to expand studies done previously on
males, this core promotes research on sex differences in life span and patterns of aging. The Cell
and Tissue Core involves expanding an existing
human cell bank and establishing a human tissue
bank. The Brain Bank Core makes available brain
tissue from human subjects with an emphasis on
nonpathologic brain specimens.

Kimmel and Whitney Elected to Board of Trustees
Jefferson
HealthCARE
rpie Board of Trustees of Thomas
"The March," Mr. Kimmel
Since 1994 he has served as Director
of Academic Affairs at the Medical
Jefferson University has elected
spearheaded a program last year in
Opens in Voorhees
A

s part of its continuing effort to

two new members: Sidney Kimmel
and Leslie W. Whitney, M.D.

Washington, D.C., that resulted in an
unprecedented 16 percent increase of
$400 million in federal funding for
cancer research.

.1.provide health care services to
the South Jersey population,
Jefferson HealthCARE-Voorhees has
opened in the Voorhees Corporate
Center. The new facility houses
medical offices and general x-ray
services. A wide array of specialties
are represented, in addition to

Mr. Kimmel is founder and chairman
of the Jones Apparel Group, a leading
women's apparel manufacturer. He
has long been active in supporting
medical, cultural, and educational
organizations nationally, with a
particular focus on the Delaware

primary care.

Valley.

center, currently under construction
as the new home of the Philadelphia
Orchestra.

"Now we can care for patients who
are seeing Thomas Jefferson
University Hospital physicians, but
don't want to travel too far from
home," explains Jefferson Hospital
President and CEO Thomas J. Lewis.
"Many of our doctors who practice in
Center City already treat patients
who live in South Jersey. By bringing
the doctors closer to where they live,
and providing a variety of specialists
under one roof, we have shortened

Mr. Kimmel is perhaps best known to
Jeffersonians through his generous
gifts to establish the Kimmel Cancer
Center of Jefferson Medical College
and the Kimmel Cancer Institute for
research. As National Chairman of

Leslie W. Whitney, M.D. has pursued
a long and noteworthy career in
medicine in Delaware and
Philadelphia, with an emphasis on

the distance between Jefferson and
our patients."
Jefferson Hospital was named this
year by U.S. News and World Report
as one of "America's Best Hospitals"
for cancer treatment, cardiology,
gastroenterology, geriatrics,
gynecology, neurology and
neurosurgery, orthopaedics,
otolaryngology-head and neck
surgery, respiratory disorders,
rheumatology, and urology. it

College. Since 1995 he has been
Executive Director, Delaware
Institute for Medical Education
(DIMER) and since 1994 has chaired
faculty committees on quality
improvement, clinical care, and
credentialing for the Medical Center
of Delaware in addition to serving as
Medical Director, Health Services
Corporation, Medical Center of
Delaware. Dr. Whitney is a Trustee of
the Medical Center of Delaware
Foundation. He has been principal
investigator for numerous cancer
research projects in Delaware through

cancer treatment, education, and
research.

the years. it

ninth leading cause of death in the
world, accounting for a million
deaths annually.

The mouse model will enable
scientists to target the liver with viral
gene therapy, decide which virus
proteins are targets for immunological responses, and identify the
parts of the immune system that are
important for targeting the virus.

Transgenic Mouse Model, from page 19
The mouse model may also have
implications for developing drugs to
fight a major international public
health dilemma. "One of the largest
problems in the field of hepatitis B is
what to do with carriers at high risk
for the development of chronic liver
diseases," Feitelson notes. "We have a
vaccine to prevent the disease and
tests to screen the blood supply, but
there are still an estimated 350
million HBV carriers at high risk of
developing hepatitis, cirrhosis, and
liver cancer." As many as two billion
people worldwide are infected with
the virus, though they are not
carriers. Chronic HBV infection is the
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Mr. Kimmel has produced major films
through his entertainment company
and has been the lead supporter of his
native Philadelphia's performing arts

Center of Delaware, and since 1996 as
Assistant Dean at Jefferson Medical
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While scientists know that the
pathogenesis of chronic hepatitis B is
due to immune responses against the
virus-infected liver cells, "There are
basic science questions about the
pathogenesis that are unsolved and
which can be addressed using our
new mouse model," Feitelson says.
"We can test drugs in the liver against
the virus in the absence of disease—if
we don't reconstitute the immune
system. Or we can replace the
immune system and then ask what
the drug does to the virus and the
disease."
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The model has implications for
understanding other diseases as well.
"Scientists can use the same approach
to study the pathogenesis of immunemediated diseases involving other
infectious agents—and to study
certain autoimmune diseases," he
explains. "With something that is
foreign, you can reconstitute the
immune system and look for
development of pathology to that
foreign protein." it
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The "Best" Internet Sites about Health
en Jefferson neuroscientist Jay
. Schneider, Ph.D., tried to
navigate the Internet in search of
information to help a neighbor learn
more about his daughter's rare brain
tumor, he was perplexed by the
difficulty of wading through vast
reams of material, some of it blatantly
inaccurate.

W
Arthur H. Brownstein '80 is the
author of Healing Back Pain Naturally,
published this year by Harbor Press
of Gig Harbor, Washington. The book
has been endorsed by Andrew Weil,
M.D., a well known advocate of
alternative therapies. Dr. Brownstein

SSveraTZENTI-e
ECKTROgy.

holds an M.P.H. in addition to his M.D.
degree, and is a Clinical Instructor of
Medicine at the University of Hawaii.
He lives in Hanalei.

How, he asked, could the average
person possibly separate the helpful,
accurate information from the useless
and misleading?

Richard Spaide '81, author of
numerous papers, book chapters, and
invited lectures, had a textbook,
Diseases of the Vitreous and Retina,
published by W. B. Saunders Company
in August. Dr. Spaide has a large
practice in New York City, and a
faculty affiliation with New York

Five Jefferson alumni contributed to
the new centennial edition of The
Merck Manual. Seventeen editions of
this well known book have been

Medical College. His wife Chang Ho
Spaide is an '83 Ph.D. graduate of
Jefferson.

published since 1899 as a nonprofit
informational source by Merck and
Company, the pharmaceuticals firm.

"A typical search may result in a list of
thousands of sites containing your
search word or phrase," says Dr.
Schneider, a renowned Parkinson's
disease expert and Professor of
Neurology at Jefferson. "Out of those
sites, some have erroneous medical
information, and some are simply
trying to sell products."

AIDE

DISEASES
THE RETINA
AND VITREOUS

Mark R. Stein '68 of Palm Beach
Gardens, Florida is the Editor of
Gastroesophageal Reflux Disease and
Airway Disease, published this year by
Marcel Dekker, New York as part of
the series "Lung Biology in Health
and Disease." Dr. Stein's volume
comprises 364 pages with illustrations. Among the 13 contributors are
Lyndon Mansfield '68 of El Paso,
Texas and Stephen McGeady, M.D.,
a faculty member in pediatric allergy
and clinical immunology at Jefferson
and the duPont Hospital for Children.
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More than 10 million copies in 16
languages have been sold in this
century. Rest assured, the content has
changed: where the 1899 manual
recommended leeches for laryngitis,
this year's volume discusses resistance
to antibiotics. Instead of tobacco as a
treatment for asthma, there's now a
chapter on smoking cessation.
The 1999 section on myoneurogenic
disorders and prostate disease was
contributed in part by Gerald Andriole
'78, Chief of Urology at Washington
University School of Medicine in St.
Louis. Stephen Finn '92 of Georgia
wrote on gastritis and peptic ulcer
disease. John H. Bland 144, a Professor
Emeritus at the University of Vermont
College of Medicine, covered
osteoarthritis and neurogenic
arthropathy, and Herbert Patrick '77,
a Jefferson faculty member and expert
on pulmonary medicine, discussed
sarcoidosis. James V. Macke!! '69 of
Maple Glen, Pennsylvania'was a
chapter reviewer.
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Finding no consumer guide to help, he
and a colleague decided to write one.
Dr. Schneider and fellow neuroscientist Theodore I. Lidsky, Ph.D.,
Director of the Laboratory of
Electrophysiology at the Institute for
Basic Research on Developmental
Disorders in Staten Island, New York,
created a guide entitled The Doctor's
Always In. Published by
Neurolnformatics Publishing, it
describes more than 1,100 "best"
Internet sites on health and medical
information.
The book's 25 chapters are broken
down by body system and specific
disease category, such as AIDS,
allergies/asthma, cancer, gastroenterology, mental health, or sports
medicine. Nearly every chapter begins
with a "general information resources"
section describing information on a
range of topics. This is followed by
descriptions of more specific sites.
Each entry gives the web address and
explains what the consumer can
expect to find.
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In the chapter on cancer, for example,
the first few pages describes more
general cancer information sites. The
rest of the chapter focuses on specific
sites, such as those for brain tumors,
childhood leukemia, and breast
cancer. A chapter on alternative
medicine offers descriptions of sites
focusing on herbal medicine,
medicinal plants and foods,
chiropractic, and homeopathic
medicine.
The authors also include a chapter
entitled "General Medical Resources,"
which describes sites providing
material about drugs, clinical trials,
and consumer information about
doctors.
"In researching the book, we combed
through thousands of sites for more
than six months to find those that
had reliable information. Many of
these were from government organizations, foundations, and academic
institutions," Dr. Schneider explains.
Some institutions such as Jefferson
(www.jeffersonhealth.org) provide
both timely news and comprehensive
information on a wide range of
medical subjects.
"We also provide some cautionary
notes about getting medical
information from the Internet, which
can be very different than getting it
from a book or a physician.
"The book makes you a more
educated consumer, allowing you to
discuss your condition, medications,
or side effects with your doctor," Dr.
Schneider says.
The authors also include an
explanation of how the Internet
works, including such features as
bulletin boards, listservs, and search
engines.

Jefferson Art Book Now Available
A unique addition to the annals of Jefferson history, "ADORN THE HALLS": History of the Art Collection at Thomas Jefferson University,
has been written by Julie S. Berkowitz, the University Art Historian. The 725 page book was edited by Malcolm Clendenin, Editor of the Jefferson
Alumni Bulletin.
The richly illustrated medical/art book describes the origins and development of the Jefferson collection, comprising paintings, sculptures,
architecture, decorative arts, photographs, prints, drawings, and rare medical books. Following a survey of the collection as a whole, 10 chapters
trace Jefferson's chronological history in the context of its portraits and other art works which collectively delineate the spirit of the institution.
The final two chapters treat nonmedical art objects (such as landscapes) and European medicine and its practitioners.
The handsome volume contains black and white photographs of 429 art works (several with closeup details), and full color photographs of 28
objects. The hard cloth cover is stamped in gold, and the dust jacket features Thomas Eakins's The Gross Clinic. This monumental painting is
discussed in its own chapter, preceded by a chapter treating Eakins as a scientist and his relationship with Jefferson Medical College.
Send Mail Order Form to: Thomas Jefferson University Bookstore, 224 S. 1 1 th St., Phila., PA 19107;
for further information call (888) TJU-BOOK or fax (215) 923-1844
Quantity
Each book

Amount

$79.00

UPS Shipping per book

6.00

Each additional destination

6.00

History of the Art Collection
at Thomas Jefferson University

TOTAL
Check or Money Order Enclosed, Drawn on a U.S. Bank in U.S. Currency
Please Make Check Payable to: Thomas Jefferson University Bookstore
For Visa/MasterCard/AmericanExpress/Discover
Account No.
Expiration Date
Signature
Name
Address (no P.O. box, please)
Julie S. Berkowitz

Telephone No. (

The Holidays Are Here—Please Send a Book as a Gift to:
Name
Address (no P.O. box, please)

Please enclose your own gift card with message, and the bookstore will send it with your gift.

FACULTY KUDOS
Lankford Receives Biomedical
Engineering Grant from the
Whitaker Foundation

Michael A. Alexander, M.D., Clinical Professor of
Rehabilitation Medicine at Jefferson and an expert on
pediatric rehabilitation, takes office at the end of 1999
as President of the Medical Society of Delaware.

Paola Luzi, Ph.D., Research Instructor in Neurology,
has received an award of $30,000 from the Hunter's
Alexander
Hope Foundation of Orchard Park, New York. The
grant supports Dr. Luzi's pilot research into gene
therapy that may provide a novel delivery system for treatment of Krabbe
disease.
Krabbe disease (globoid cell leukodystrophy) is a genetic disorder resulting
from the deficiency of the lysosomal enzyme galactocerebrosidase. It is characterized by the progressive loss of central and peripheral myelin (a protective
covering that insulates nerve cells), leading to early death. The most common
form of this disease affects babies, who usually die by two years of age. Krabbe
disease also affects older children and adults.
Presently, there is no cure for this condition, and treatment has been
limited to cold blood and bone marrow transplantation in presymptomatic and
later-onset patients. The gift from Hunter's Hope will enable Dr. Luzi and her
colleagues to investigate possible gene therapy.
Hunter's Hope, founded in 1997, has raised more than $2 million to benefit
research on Krabbe disease, and has also increased public awareness of this
disease and other leukodystrophies (which cause degeneration of the white
matter of the brain).

Michael Rhodes, M.D., Professor of Surgery at Jefferson and Chair of Surgery
at Christiana Care Health System in Wilmington, Delaware, received the
Curtis P. Artz Award from the American Trauma Society during the annual
meeting in Washington, DC in April. The award is presented to individuals for
outstanding long term contributions in the field of trauma.

Henry Rosenberg, M.D., Professor and residency director in Jefferson's
Department of Anesthesiology, has been named President of the Malignant
Hyperthermia Association of the United States. MHAUS provides information
to professionals caring for patients with malignant hyperthermia or
neuroleptic malignant syndrome. Malignant hyperthermia is a rare inherited
condition characterized by a rapid, extreme, and often fatal rise in body
temperature following the administration of general anesthesia. Neuroleptic
malignant syndrome is a dangerous side effect occasionally seen in patients
taking neuroleptic drugs for psychotic symptoms such as paranoid delusions
and auditory hallucinations.
Dr. Rosenberg is Editor-in-chief of the American Journal of Anesthesiology
and is an article reviewer for several journals. He has published extensively on
malignant hyperthermia.

E

dward Lankford, M.D., Ph.D.,
Assistant Professor of Pathology,

was one of 20 researchers from 19
universities who recently received
Biomedical Engineering Research
Grants from the Whitaker
Foundation.
These grants help promising new
investigators establish research
careers. Dr. Lankford's award of
$210,000 will support his research
on the functional recovery of failing
cardiomyocytes. He will explore
changes that occur in human hearts
after they undergo placement of
implanted pumps. Such devices,
which assist the failing heart by
pumping blood, are inserted in
individuals awaiting heart
transplants, who otherwise might not
survive until a heart is available.
It has been observed that patients'
hearts, when supported by these
devices, shrink and begin pumping
more strongly, and Dr. Lankford
hopes to understand the cellular
changes that are responsible for this
improvement. This, in turn, may
enable physicians to understand why
the heart function deteriorates and
lead to a dramatically better
alternative to heart transplantation
for treating heart failure. The
research requires the design,
construction, and use of a new device
to study very small samples of
human heart tissue, especially the
tissue's ability to contract and
perform work.

"Since heart failure is the most
common reason for hospitalization
today and there is an insufficient
number of hearts available for
transplantation, most patients will
not receive transplants," Dr.
Lankford noted. "Therefore, we need
to be able to coax the failing heart
into sustaining the patient's life and
some level of activity for as long as
possible. This research should help
us understand how the heart muscle
cells adapt to the load imposed on
them, and allow us to design dramatically new therapy for heart failure.
We are very excited about the
potential of this research that we will
be able to conduct with the threeyear Whitaker Foundation grant."
The Whitaker Foundation of
Rosslyn, Virginia is a private,
nonprofit foundation dedicated to
improving human health through the
support of biomedical engineering. It
was established in 1975 upon the
death of U. A. Whitaker, founder and
Chief Executive Officer of AMP
Incorporated, now the world's largest
manufacturer of electrical connectors
and connecting devices. The
foundation has awarded more than
$450 million to colleges and universities for faculty research, graduate
fellowships, and program
development in biomedical
engineering.
Another recipient of a Whitaker
Foundation grant is Jefferson
alumnus Mark Brezinski
M.D./Ph.D.'88, who currently teaches
at Harvard Medical School and
Massachusetts General Hospital.
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STUDENT ADMISSIONS
The* Class of 2003

J

efferson students are a
very select group: the
223 members of the Class
of '03 were chosen from a
total of 8,171 who applied
for admission. Members of
this class hail from 22
different states as well as
Canada, and attended 91
different colleges. Forty-six
percent of the class is
female. No fewer than 34
students already hold
master's degrees; two have
Ph.D.s. Ages range from a
very young 19 up to a wise
44. The age range reflects
the fact that many have
already achieved
distinction in other careers.

JAMA Study Proves That PSAP Brings
Family Physicians to Underserved Areas
I

espite an oversupply of
physicians in the United States,
statistics show that rural areas

PSAP students follow a curriculum
similar to their non-PSAP classmates,
but receive training in small towns

continue to suffer from a shortage of
physicians, especially family doctors.
In response to this maldistribution,
Jefferson Medical College initiated the
Physician Shortage Area Program
(PSAP) in 1974 to increase the
number in underserved regions,

and are guided by an academic
advisor from Jefferson's Family
Medicine Department.

especially in Pennsylvania.
Krissa George balances the books with
motherhood: on the first day of the semester,
bookbag over her shoulder, she tends to young
Annalise. Before coming to Jefferson, Krissa was
a health administrator for an international
finance firm, as well as a mother of two.

Health care is familiar to many of them: there are a handful of nurses, a clinical
epidemiologist, a researcher in an academic program in bone marrow
transplant, an infants' nutrition counselor, a pharmacist, a pediatric audiologist, a researcher in a hospital department of maternal-fetal medicine. One
has been a professional counselor for victims of sexual assault or domestic
violence.
One new student spent two years as a Peace Corps volunteer in Guinea, West
Africa, teaching calculus in French to high school students. Another
volunteered in Croatia, working with refugee children. A third volunteered in
Mother Theresa's hospital in Calcutta, India.
We know that Jefferson students can perform: there are a concert cellist, a
classical guitarist, a professional clown, and a TV comedy writer. But
management skills are not lacking: one freshman was a director of international sales for a computer game company. And technical skill is taken for
granted: there are several engineers, including one specializing in submarines.

Now 25 years old, the PSAP, which
admits approximately 15 students per
year, graduates 12 percent of all rural
family doctors in Pennsylvania. A
retrospective study demonstrating
PSAP's effectiveness in easing the
shortage of rural physicians appeared
in the January 20, 1999 issue of the
Journal of the American Medical
Association.
The program recruits students who
have grown up in a rural setting and
who are committed to practicing
family medicine in a similar area. "The
selection process of students for the
PSAP has been key to the successful
retention rates," explains Howard K.
Rabinowitz, M.D., Professor of Family
Medicine at Jefferson and director of
the PSAP since 1976.

The Class of 2003 was selected under the leadership of Benjamin Bacharach
'56, who served until recently as Associate Dean for Admissions, and is now
Associate Dean for Alumni Relations and Acting Executive Director of the
Alumni Office. The selection of next year's entering class is now being
overseen by Clara A. Callahan PD'82 as Associate Dean for Admissions and
Student Affairs.

it

At right: Associate Director of Admissions Grace Hershman and Assistant Dean
for Student Affairs Karen Glaser, Ph.D. with first year student Denise Markmann
(second from right) and her parents Margaret and William Markmann ORS'79
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The JAMA study used current data on
206 PSAP graduates from the classes
of '78 to '91 who are presently
practicing family medicine in
underserved areas of Pennsylvania.
They were compared against all
allopathic (M.D.) medical school
graduates in the state, and against all
U.S. and international graduates. The
PSAP graduates were also compared
against their non-PSAP peers from
Jefferson Medical College regarding
their U.S. practice location, medical
specialty, and retention for the past
decade.
Results show that PSAP graduates,
who represent only one percent of the
graduates of Pennsylvania's seven
allopathic medical schools, account
for 21 percent of family physicians
practicing in rural Pennsylvania
coming from those medical schools.
Among all national and international
medical school graduates, PSAP
continued

alumni represent 12 percent of all
family physicians in rural
Pennsylvania. Results were similar for
PSAP graduates practicing in other
underserved regions.
Overall, PSAP alumni were eight times
more likely than their non-PSAP
classmates at Jefferson to practice
family medicine in a rural area of the
U.S. Program retention was also found
to be high, with the number of PSAP
graduates practicing in underserved
areas being approximately 90 percent
of the number practicing 10 years ago.
Rural family practice truly means care
for the family as a whole. Physicians
treat each generation, providing
general medical attention plus such
specialty services as delivering babies
and minor outpatient surgery.

A visit to Dr. Devlin is not too scary.
both inpatient and outpatient
settings, giving him hands-on
understanding of how to work in a
relatively isolated area.
"It means providing a wide range of
care for the entire family," Devlin
explains. In Brockway, he practices
primary care in the sense most city
dwellers know it, but also delivers

"With more rural residents in
Pennsylvania than in any other state in
the nation, the medical needs of this
population are great, and Jefferson's
PSAP is meeting these needs to a large
extent," Dr. Rabinowitz says.

babies and assists with various
surgeries such as gallbladder removal,
hysterectomy, and caesarean sections.
Dr. Devlin treats grandparents for the
general health problems of old age,
while delivering their great-

For James Devlin '85, medical training
began as a child when he accompanied
his father, a family physician, on
house calls in Brockway, a small rural

It'll be as good as new in no
time, Dr. Devlin assures.

grandchildren. "There is a limited
number of subspecialists here,
broadening the scope of what I am
called upon to provide."

"The PSAP's goal was to return me to

family he had known for a lifetime.

I am able to care for patients who are

"Practicing in the country allows me

also my friends. This is family

to learn not only my patients' medical

medicine in its purest form.

histories, but also their family histories

Interestingly, it's also very modern: in

and life experiences," he says.

the past decade there's been more and
more emphasis nationwide on
primary care."

to conduct some interesting academic

Shortage Area Program, Thane Turner

research," he says. "I was able to build

of Lock Haven, Pennsylvania has

relationships with my mentors on the

experienced the program's benefits

Jefferson faculty, who showed me the

both as a student and as a teacher.

scope of what you can do in family
medicine."

Enjoying the history and people of
Lock Haven, Dr. Turner knew that he

Turner put his training to work in a

wanted to return there to practice

group medical practice in Lock Haven,

Stuffed animals lend support on the right as the boss consults Dr. Turner.

today practices family medicine in the
same town, bringing his two children
with him on house calls, much the
way his father did a generation ago.
"Growing up in Brockway, I watched
my father get to know his patients as
people, by really sharing in their
lives," says Dr. Devlin. "I knew that I
wanted to return to this atmosphere
and practice medicine in much the
same way. The PSAP gave me the
training I needed to care for people."
Through the PSAP, Dr. Devlin was
able to take his clinical rotations
during his junior and senior years of
medical school in rural parts of
Pennsylvania. This exposed him to
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training during my clinical years of

A '93 graduate of Jefferson's Physician

Area Program at Jefferson, Devlin
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"The PSAP allowed me to complete
medical school in rural areas, and also

community in western Pennsylvania.
A graduate of the Physician Shortage

medicine, caring for the friends and

the place I had loved since childhood.
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where he lives with his wife and two
children. He provides comprehensive
care—everything from treating
patients for the flu to delivering
babies, performing minor surgeries
(such as suturing or mole removal),
and casting minor fractures.
Like all PSAP participants, Dr. Turner
studied under a physician preceptor
for six weeks in a rural part of
Pennsylvania in his fourth year of
medical school. He found the
experience so beneficial that he has

since served as a preceptor for current
Jefferson students.
"Being a preceptor has allowed me to
experience the benefits of the PSAP
from the other side," Turner says. "I
was able to keep my teaching skills
sharp, and to bond with my student
in much the same way as I had with
my advisor. The PSAP allows both
students and teachers to learn the
dramatic differences between the
practice of medicine in Center City
Philadelphia and rural
Pennsylvania." (4)

Zalewski Appointed to William Wikoff
Smith Professorship in Cardiac Research
Technology Illuminates a Work of Art

Andrew Zalewski CD'84, Professor of Medicine, has been appointed to the
William Wikoff Smith Chair in Cardiac Research. Dr. Zalewski, who is the
Director of Jefferson's Cardiovascular Research Center in the Division of
Cardiology, is a leader in the field of vascular biology and interventional
cardiology. He and his group have published extensively on the mechanisms of
vascular repair under physiological and disease-related conditions. Under Dr.
Zalewski's direction, Jefferson's Cardiovascular Research Center has become a
nationally recognized program bridging basic sciences with clinically relevant
issues of coronary restenosis, bypass graft disease, and atherosclerosis.
A native of Warsaw, Poland, Dr. Zalewski received his M.D. degree from
Warsaw Medical School, where he did his internship and residency. He has been
associated with Jefferson since 1983, when he initially served as a Fellow in
Cardiology. He is a member of the American Heart Association, the American
Physiological Society, and the North American Vascular Biology Organization.
The William Wikoff Smith Chair was established by the W. W. Smith Charitable
Trust of Newtown Square, Pennsylvania. During this past year, the trust
completed its commitment to endow the chair. "This grant was given as a
reflection of Mr. Smith's exceptional vision and his desire to enhance medical
excellence," said Mrs. Mary L. Smith, his widow and trustee of the Smith Trust.
"It is an honor to be a partner with Jefferson and its professionals who are at the
forefront of heart research." —Roslyn Levine

The university's Portrait of Professor Benjamin H. Rand, a major early
painting by Thomas Eakins, was studied over the summer by experts from
the Philadelphia Museum of Art using infrared refiectography. Above, Mark
Tucker, chief painting conservator at the museum, aims a camera which
produces a greatly magnified view on the monitor at left. Infrared light has
the ability to penetrate layers of paint, revealing preliminary underdrawings
and compositional grids that Eakins made on the canvas. This provides a
new understanding of his working methods as an artist. The three Eakins
portraits at Jefferson were among many of the artist's works studied by the
team. Looking on during the process are curators, conservators, and photographers from the museum. Coordinating Jefferson's participation in the
study was Julie S. Berkowitz, University Art Historian.
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Dr. Zalewski; Ms.
Deborah J. McKenna,
who is a member of
the trust's staff and a
daughter of Mrs.
Smith; Mrs. Mary L.
Smith; Mrs. Louise A.
Havens, grant
administrator of the
trust and a daughter
of Mrs. Smith; and
University President
Paul C. Brucker, M.D.

December 1999
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President's Club Dinner Celebrates Successful Completion of the Jefferson 2000

M

rs. Samuel M. V. Hamilton, longtime university trustee and Chairman of
the Jefferson 2000 Fund capital campaign, was the honored guest at this
year's President's Club dinner. The annual dinner dance, hosted by President
Paul C. Brucker, M.D. and his wife Joan, was a glittering celebration of Jefferson's
175th anniversary and the extraordinary philanthropy that recently brought the
comprehensive fund-raising effort to a close, ahead of schedule and ahead of its
$200 million goal.
The event, which acknowledges Jefferson's most generous and loyal benefactors,
was held Saturday evening, October 2, at the Crystal Tea Room. The evening's
program paid tribute to Mrs. Hamilton for her exceptional philanthropic
leadership at Jefferson, and recognized 22 new President's Club Fellows and 13
new members of the Winged Ox Society.

Jack Farber, Chairman of the Board of Trustees of Thomas Jefferson University,
made a special presentation to Mrs. Hamilton. "We have you to thank, Dodo, for
leading this campaign to victory," he said. "The more than $200 million you
have inspired all of us to raise will benefit countless patients now and in the
future, educate generations of physicians and other health care professionals,
and advance vital research."
Mr. Farber unveiled a photographic portrait of Mrs. Hamilton as a gift to her
and her family. An identical one will be displayed at Jefferson, to be replaced
later by an oil portrait of Mrs. Hamilton.
"Dodo's steadfast support has had a major impact on this institution," Mr.
Farber said. In addition to leading the successful Jefferson 2000 Fund campaign,
Mrs. Hamilton has been a member of the Board of Trustees for 27 years, and a

"One hundred and seventy-five years ago, our founders had a mission, and I am
proud to say it has been fulfilled," Dr. Brucker said. "This is a very different

member of the hospital's Women's Board for more than 40 years.

world than it was in 1824. Both eras have their unique challenges, but I think our
founders would be pleased to see how Jefferson has flourished."

During the program, Mrs. Hamilton acknowledged special donors. "For over
two decades, new Fellows of the President's Club have received gold-headed
physicians' canes, symbolizing healing, and acknowledging their exceptional
generosity," she said. In announcing the names of the new Fellows, benefactors

"We did it!" Mrs. Hamilton told the group. "The Jefferson 2000 Fund has reached
its goal—in fact exceeded it. The grand total is $202 million in gifts and pledges."
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The 22 new Fellows of the President's Club include: postgraduate alumnus
Thomas Connelly D'85; Mrs. Catherine Datz; Michael D. Ellis '70; Mr. and Mrs.

Bottom row, from left: Dr. and Mrs. Robert Capizzi and Mrs. Hamilton;
Mrs. Hamilton is congratulated on her portrait by Mr. and Mrs. Farber and
Dr. and Mrs. Brucker;
Mrs. Benjamin Bacharach with Dr. Bacharach '56, Associate Dean for Alumni
Relations and Acting Executive Director of the Alumni Association;

John Estey; Martin Feldman '62; Mr. and Mrs. Stanford Frank; Mr. and Mrs.
Robert French Jr.; Joshua Gold; George Hollander '39; Mr. and Mrs. Harold
Honickman; W. Bosley Manges S'44; Alice T. Muffly; John J. Murray; Mr. and
Mrs. Daniel Polett; Dr. and Mrs. Robert Poole III '53; Robert A. Shopbach, M.D.;
Grafton F. Sieber '57; and Paul E. Stroup '52.

Mrs. James Kelly '39 with Dr. Brucker.
Middle row: Dr. and Mrs. Stanton Smullens '61;
James Stratton and Mr. Farber;
Julian Feldman '58 with William Keane, M.D. and Ronald Bolognese, M.D.;
Eric Hume ORS'83 with Dr. Brucker and Jerome Cotler '52 and Mrs. Hume.

photos Robert Neroni—montage Med. Media Services

whose total support has been $50,000 or more, Mrs. Hamilton reported that
there were a record number of canes to present.

Richard L. Steelman Ph.D.'77 attended the dinner and received his gold pin
signifying membership in the Winged Ox Society, which honors benefactors
who have contributed $10,000 or more to Jefferson in the previous fiscal year.
New members this year are: Mrs. William M. Cashman; Dr. and Mrs. Eui K.
Chung; Dr. and Mrs. Won S. Cynn; Edward A. Emmett, M.D.; Mr. and Mrs.
Stephen Klein; Karl G. Klinges '56; Mr. and Mrs. Leonard Korman; Mr. Howard
S. Kroop; Helyn L. Romberg; Mr. and Mrs. Frank Schreiner; Frederick A.
Simeone, M.D.; and Mrs. Henry Stofman.
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Top row: Dr. and Mrs. Poole;
Mr. and Mrs. Michael Murray and Mr. and Mrs. James Datz;
Mrs. James Corwin '56 with George Gowen '52 and Dr. Corwin;
(between rows) Dr. Brucker and Mrs. Muffly;
(at top) Dr. and Mrs. J. Wallace Davis '42 and Mrs. Stofman;
(between rows) Marianne Ritchie '80 with Dr. and Mrs. Everett Gordon '37 and
Stuart Gordon '81;
Mr. and Mrs. Honickman.
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A Holiday Gift for You and Jefferson
The Charitable Gift Annuity
Give by December 31, 1999, to save federal income taxes on April 15, 2000.
You work hard to build financial security for yourself and those who depend on you.
However, federal income taxes can take a significant bite out of your assets.

There's Still Time — Jefferson Can Help You Save on Your 1999 Taxes.
With a minimum gift of $10,000, you can establish a charitable gift annuity
and benefit future generations of Jeffersonians while receiving:
• A federal income tax deduction
• Guaranteed income for life, a portion of which may be free of income tax

Charitable Gift Annuity*

Fixed life Income to
John and Mary:
$680 per year.
A Portion May Be Tax Free.

John and Mary Donor
Ages: 70 & 70
Asset Transfer: $10,000

1•10•■•••••■

Charitable
Gift Annuity
Managed by Jefferson

Income Tax Deduction:
$3,309
and
Reduced Capital Gains Tax

Gift of Principal
to
Jefferson

For a personalized charitable gift annuity calculation or more information,
please call Frederick "Fritz" Ruccius or Lisa Watson toll-free at 1-877-JEFF GIFT [1-877-533-3443].
You may also email your questions to jeff trust@ mail. tju.edu
or complete and send the attached business reply card to the Jefferson Development Office.

A Jefferson Planned Gift: An Investment in the Future
* This advertisement is for illustrative purposes only and is based upon the Federal tax laws in effect on September 30, 1999, and
should not be construed as tax advice. The laws and regulations of individual states are not discussed. Please note that individual tax circumstances may vary
and the laws are subject to change. We recommend you consult your own tax advisor before making any financial decisions.

Maus, Flanagan,
and Rosenwasser

Neurosurgery and Ophthalmology
Collaborate on Sophisticated Operation
n a combined operation that brought

orbit so they can be removed without

together state-of-the-art ophthalmology

disturbing the brain," says Robert

and neurosurgery, physicians at Will Eye

Rosenwasser, M.D., Chief of the Division

Hospital removed a benign but recurring

of Cerebrovascular Surgery and

tumor from the optic nerve of patient

Interventional Neuroradiology at Jefferson

Dolores Breskie. The five-hour operation

and Wills. "But this one was very deep

had a sight-saving, as well as a life-saving,

and very far back, almost resting on the

outcome for Ms. Breskie, who had already

optic nerve. That fact moved it into the

lost vision in one eye.

category of brain surgery."

"It was the third time the tumor had

Dr. Rosenwasser conducted the first part

grown back," says Joseph Flanagan '63,

of the surgery, removing a portion of the

Professor of Ophthalmology at Jefferson

skull and orbit, and slightly shifting the

Medical College and the attending surgeon

brain to enable the ophthalmic surgeons

who had removed the earlier growths. "It

to reach the growth.

wasn't malignant, but it was behaving the
way a malignant tumor does—aggres-

"We were looking down at the eye," says

sively," says Marlon Maus '85, an associate

Daniel Elizondo, M.D., an oculoplastic

surgeon on the Wills oculoplastic service.

fellow who assisted in the surgery, "and

"It had spread quickly, covering her optic

could clearly see the tumor and all of the

nerve, her sinuses, and several muscles. It

tissue it had covered."

had also grown very large."
The next phase was Dr. Flanagan's, who,
So large, in fact, that by the time of the

assisted by Dr. Maus, spent three hours

operation, the tumor was the same size as

removing the tumor. "It's a procedure that

Ms. Breskie's eye, and it was pushing

takes a lot of time because we try to get all

against it, causing it to bulge unnaturally.

of the tumor, or as much as possible,"

"Her appearance just added to her

Flanagan explains.

distress," says Dr. Flanagan.
Once it had been removed, steps were

pr

But it was the direction the tumor was

taken by Dr. Rosenwasser to decrease the

taking that especially concerned the

chance of its return and to preserve the

physicians. "It was growing dangerously

eye. This required removing areas of the

close to the area of the brain where the

muscles and nerves which had been

optic nerve centers the orbit," Flanagan

invaded. "Although she has no vision in

explains, "so it was likely to spread into

the affected eye, it was very important to

the brain." It was also likely to cost her the

her not to lose her eye," Rosenwasser says.

vision in her good eye.

An Albanian boy watches the convoy of American army vehicles pass by
(photo by Ben Starnes '92).

Caring for the Ill and the Wounded in

Kosovo
mong the Jeffersonians who
contributed to humanitarian
efforts in the Balkans this past spring is
Benjamin Starnes '92. Starnes is senior
surgeon of the 212th Mobile Army
Surgical Hospital—the only remaining
MASH in the U.S. Army—which was
deployed to Tirana, Albania with Task
Force Hawk in April 1999. They were
the medical support for the proposed
deep strike of Apache helicopters into
Kosovo. In Albania they saw more than
700 patients and did
28 operative cases.
Providing care was
complicated by the
sheer numbers of
refugees.

NATO peacekeeping force. "The
initials KFOR are painted on
everything that has any connection
with it," Starnes says.
This fall Starnes was re-stationed in
Heidelberg, Germany where he leads
a general surgery service. His team is
scheduled to return to Kosovo in
March 2000 for six months as part of
continued peacekeeping efforts. It's a
matter of helping wounds to heal.

Starnes also
journeyed to Camp
Bondsteel in Kosovo.
The MASH then
moved to Macedonia
to back up Task
Force Falcon and
the implementation
Starnes (right) performing a diagnostic peritoneal lavage
of Kosovo Force, the
in the trauma resuscitation bay in Albania last spring

After the cranial closure by Dr.
Under these circumstances, the surgical

Rosenwasser, Drs. Flanagan and Maus

Starnes (right)

approach changed, evolving into a

rebuilt the bony area from the patient's

and a fellow
surgeon in front
of the MASH
in Tirana

procedure requiring both an ophthalmic

forehead to the cheek that had been

surgeon and a neurosurgeon. Furthermore,

destroyed by the tumor.

unlike many of the ophthalmic/neurosurgical procedures done at Wills, it was

"We saw her four hours later and she was

going to be open-skull surgery.

wide awake, alert, and feeling very well,"

"We do a lot of ophthalmic tumor

able to save my eye," declared Ms.

surgeries jointly, but most are only in the

Breskie shortly afterward.

Flanagan recalls. "I'm grateful they were

IN MEMORIAM

Howard E. Dicker '29 died February 6,
1999. A member of the Alpha Omega
Alpha Honor Medical Society, he was in
general practice in South River, NJ from
1931 to 1970. He is survived by his wife,
Alice.

Ellwood City Hospital, Ellwood City, PA,
and Jameson Memorial and St. Francis
Hospitals, New Castle, PA. He is survived
by two daughters and four sons. Son James
L. II is Jefferson '72 and son Stuart is
Jefferson '79.

Charles Duffy Sr. '30 died April 10, 1999.
He was in general practice in New Bern,
NC. He is survived by two sons and a
daughter.

Joseph" Rupp '42 died October 2, 1999.
He was board certified in internal medicine
and became a widely recognized endocrinologist. A revered teacher at Jefferson, he
received the Lindback Teaching Award in
1964, was selected by graduating Jefferson
students to administer the Hippocratic
Oath in 1967 and again in 1971, and had
his portrait presented to Jefferson by the
Class of '69. He was a prolific writer in the
field of endocrinology. A Fellow of the
American College of Physicians and a
member of the Endocrine Society and the
Society for Experimental Biology and
Medicine, he became Professor Emeritus of
Medicine on his retirement in 1981. He is
survived by his wife, Romaine, three sons
and two daughters. Son James is Jefferson
'80 and son Michael is Jefferson '84.

Samuel," Bishko '31 died July 12, 1999.
He was in general practice in Cleveland,
OH. He is survived by a son and a
daughter.
Lucian J. Fronduti '34 died August 27,
1999. Board certified in general surgery
and a Fellow of the American College of
Surgeons, he was Chief of the Surgical
Service, Citizens General Hospital, New
Kensington, PA. He is survived by his wife,
Jean Rita, and two sons. Son Robert is
Jefferson '66 and son Ronald is Jefferson
'77.
James N. Barroway '35 died September 19,
1999. Board certified in pediatrics and a
Fellow of the American Academy of
Pediatrics, he was on staff at Cooper and
Our Lady of Lourdes Hospitals, Camden,
NJ. Later he served as the Health
Coordinator for the Camden County
Division for Children. He is survived by a
son and a daughter. Son Robert is Jefferson
'64.
Charles W. Hoffman '35 died June 29,
1999. He practiced obstetrics and
gynecology in South Amboy, NJ. He was
Chief of Staff and Chief of ObstetricsGynecology at South Amboy Memorial
Hospital. He is survived by four daughters
and a son.
Louis A. Wilder '37 died August 23, 1999.
Although board certified in pediatrics, he
practiced as a family physician in
Abington, PA. He was on staff at Abington
Memorial Hospital, Abington, PA and the
Albert Einstein Medical Center,
Philadelphia, and served as the Police
Surgeon for Abington Township for 25
years. He is survived by three daughters.
Warren S. Shepherd '38 died July 14,
1999. Board certified in family medicine,
he practiced in Vancouver, WA. A Fellow
of the American Academy of Family
Practice, he was on staff at St. Joseph and
Vancouver Memorial Hospitals, Vancouver,
WA. He served as President, Clark County
Medical Society in 1948. He is survived by
his wife, Frances, two sons and two
daughters.
James L Gardner '41 died June 1, 1999.
Board certified in general surgery, he
practiced in Ellwood City, PA. A Fellow of
the American College of Surgeons and a
founding member of the American College
of Abdominal Surgeons, he was on staff at
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John" Hosay '43 died April 10, 1999.
Board certified in urology and a Fellow of
the American College of Surgeons, he was
Chief of Urology at the Jersey City Medical
Center and St. Francis Hospitals, Jersey
City, NJ and served as President of the Staff
at St. Francis Hospital. He held a faculty
appointment as Associate Professor of
Urology at the New Jersey College of
Medicine and Dentistry, Newark, NJ. He
received the St. Francis Hospital Medal of
Honor in 1987 and was selected "Urologist
of the Year" by the National Kidney
Foundation in 1992. He is survived by his
wife, Lois, four daughters and two sons.
Thomas E. Pilla 5'44 died July 4, 1999.
Board certified in internal medicine, he
practiced in Huntingdon Valley, PA. He
was on staff at Abington Memorial
Hospital, Abington, PA. He is survived by
his physician wife, Kathleen Scott, three
daughters and a son. Son Timothy is
Jefferson '82.
Henry G. Gallagher '46 died March 27,
1999. He was a family practitioner in
Dallas, PA. We have no further information
at press time.
John" Meehan '47 died August 29, 1999.
Board certified in internal medicine, he was
an attending cardiologist at Holy Redeemer
Hospital, Meadowbrook, PA. He is survived
by his wife, Dorothy, four sons and a
daughter.
Harold Reviser '49 died August 21, 1999.
Board certified in colorectal surgery, he
was a Clinical Assistant Professor at
Jefferson. He was also on staff at Methodist
Hospital in Philadelphia. He was a former
President of the Pennsylvania Society of
Colon and Rectal Surgeons. He is survived
by his wife, Bertha, two daughters and a
son.
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Juan E. Veve '49 died August 29, 1999. He
was in general practice in Fajardo, PR
where he was highly regarded for his
compassionate care and for his charity
work among his patients. He was on stall at
the Fajardo District Hospital and was a
member of the Puerto Rico Medical
Association. He is survived by his wife,
Teresa, two sons and a daughter.
Carl G. Pierce Jr. '50 died July 26, 1999.
Board certified in family medicine, he
practiced in Rehoboth Beach and Lewes,
DE. He was a Fellow of the American
Academy of Family Practice. He is survived
by his wife, Meredith, three daughters and
two sons.
Michael B. Dooley '52 died September 2,
1999. Board certified in radiology and a
Fellow of the American College of
Radiology, he was Chief of Radiology,
Phoenixville Hospital, Phoenixville, PA
where he also served as President of the
Medical Staff in 1971. He held a faculty
appointment as Clinical Assistant Professor
of Radiology at Temple University School
of Medicine. He was a former President of
the Pennsylvania College of Nuclear
Medicine, the Pennsylvania Radiologic
Society, the Philadelphia Roentgen Ray
Society, and the Chester County Medical
Society. He is survived by his wife, Bettie,
four sons and four daughters.
William F. X Coffey Sr. '53 died
September 23, 1999. An internist, he was
on staff at Fitzgerald Mercy Hospital,
Darby, PA. Interested in life insurance
medicine, he served as Medical Director,
Metropolitan Life. He also served as
Chairman, Insurance Medicine Section of
the College of Physicians of Philadelphia.
He is survived by his wife, Roseanita, five
sons and four daughters.
John W. Stoker '55 died February 20,
1999. Board certified in obstetrics and
gynecology, he practiced gynecologic
oncology in Altoona, PA. He was Chief of
Obstetrics-gynecology at Altoona Hospital,
and a consulting physician, Roaring
Springs Hospital, Roaring Springs, PA. He
served as President of the Blair County
Medical Society in 1971-72. He is survived
by his wife, Elaine, a daughter and a son.
Maurice" WardJr. '63 died September 14,
1999. He was a radiologist and practiced at
the Brandywine Hospital and Trauma
Center, Coatesville, PA. He is survived by
his wife, Marie, two sons and two
daughters. Daughter Kristine is Jefferson
'91.
Stanley." Yoder '64 died June 14, 1999.
Board certified in orthopaedic surgery and
a fellow of the American Academy of
Orthopaedic Surgeons, he practiced in
State College, PA. We have no further
information at press time.
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Stanton M. Baynes '69 died May 5, 1999.
Board certified in pediatrics, he practiced in
Bensalem, PA. He was a senior attending at
Frankford Hospital, Philadelphia, PA. He is
survived by his wife, Maxine, and four
sons.

Postgraduate Alumni
Has& Tanyol GE'54 died June 17, 1999.
He practiced in Fort Washington, PA and
was on staff at Germantown Hospital,
Philadelphia, PA and Montgomery
Hospital, Norristown, PA. His research on
hypertension and hepatic cirrhosis was
published. He is survived by his wife,
Lamia, and three daughters.
Benny G. Quinones-Alamo AN'82 died
June 29, 1992, it has been ascertained.
Other than he practiced in Rio Predras,
Puerto Rico; we have no further
information at press time.

Faculty
Hyman Menduke, Ph.D., Honorary
Professor of Biochemistry and Molecular
Pharmacology, died September 23, 1999.
He was an expert in statistics and, for 35
years, taught statistics at Jefferson and
assisted with the analysis of medical and
research data for clinicians and medical
scientists. He is survived by his wife, Clara,
a daughter, a stepson and a stepdaughter.
William C. Stainbadt, M.D., Honorary
Professor of Surgery, died August 19, 1999.
He served as Chief of Surgery, Bryn Mawr
Hospital, Bryn Mawr, PA and was a
supportive and contributing teacher in
Jefferson's surgical resident education
program. He is survived by his wife, Sallie,
two daughters and two sons.
Margaret "Linda" Gonnella died
September 16, 1999. She was the wife of
Joseph S. Gonnella, M.D., Jefferson's Senior
Vice President for Academic Affairs and
Dean of Jefferson Medical College. A
graduate of the University of Oregon, Mrs.
Gonnella moved to Wallingford 30 years
ago to raise her family. She received the
Wallingford/Swarthmore school district All
Service Award. Girl Scouts recognized her
with the Outstanding Volunteer Award.
Linda was a longtime board member and
past President of the League of Women
Voters of Central Delaware County.
Linda was a strong supporter of
Jefferson, including the Hospital Women's
Board. She was active in the Faculty Wives
Club and instrumental in organizing its
annual art exhibit.
Linda was loved by family, friends, and
community for her generous and caring
spirit. In addition to her husband, she is
survived by a daughter, two sons, a sister,
and a brother.

CLASS NOTES
'28
Paul G. Holsinger of Martinsburg,
PA celebrated his 100th birthday on
July 24. His grandson, Steve
Holsinger, wrote a tribute that
appeared in the Morrison Cove
Herald. Dr. Holsinger has devoted
many years to creating a comprehensive index of the Liebegott
Collection for the Martinsburg
Community Library. This index
contains over 20,000 different names
which he organized by hand.

'30
Leon L. Berns of Wynnewood, PA
was featured in a large article in the
Jewish Exponent, July 29, 1999. Dr.
Berns is still practicing medicine in
Philadelphia with his wife, Mildred, a
registered nurse. Dr. Berns was also
on the faculty at Jefferson for 63
years teaching the art and science of
anatomy to first year medical
students.

patients with terminal illnesses. Dr .
Levin now has an office in suburban
Connecticut in addition to New York.

'59
Albert C. Price of Lancaster, PA has
retired from the practice of pediatrics
but continues to be active as senior
advisor to the Safe Kids Program in
Lancaster County, which he founded.
Dr. Price, a pediatric cardiac
specialist, was the PA Safe Kids
Outstanding Coalition Volunteer in
1997. He was driven by the large
number of children injured or killed
in farm accidents. He and community
leaders have worked together to
promote farm safety locally and
statewide. He has been recognized for
his work among the Amish and
Mennonite farm children.

'48
Charles W. Anderson of Norfolk, VA
is now retired and no longer a
medical examiner, but is still working
in the city's clinic for sexually
transmitted diseases two days a week.

'56
Warren M. Levin is Chairman of the
Medical Advisory Board of the
Survive Until a Cure Foundation, a
national organization that promotes
various alternative therapies for

Alumni in Scranton and Wilkes Barre, Pennsylvania gathered to welcome
Jefferson leaders on September 29, at a dinner hosted by Nicholas I.
Ruggiero '66 (left) and Stephen E. Pascucci '48.
Physicians and Surgeons was ranked
number one in the country this year
by U.S. News and World Report. Dr.
Kleber tells the Alumni Bulletin that
he has "some promising new
treatment leads but no breakthrough
imminent." His unit has six major
studies underway that are funded by
the National Institute on Drug Abuse.
Kleber is a Professor of Psychiatry at
Columbia, and Medical Director of
the Center on Addiction and
Substance Abuse (CASA). His
publications include The American
Psychiatric Press Textbook of
Substance Abuse Treatment (1994),
which is widely used by professionals.

'62

'60 40th Reunion June 10
Herbert D. Reber continues to work
at developing new treatments for
heroin and cocaine addiction, a field
in which he is one of the country's
foremost experts. The unit he set up
at Columbia University College of

William V. Harrer has been President
this year of the Medical Club of
Philadelphia. "Many of our members
are in fact from New Jersey," explains
Dr. Harrer, who lives in Haddonfield
and practices at Our Lady of Lourdes.
In January he is succeeded as
President by Robert Reinecke, M.D., a
Professor of Ophthalmology at
Jefferson.

Diabetes Association, and is currently
Vice President of the International
Diabetes Federation.
Amylin Pharmaceuticals is a
pharmaceutical company focusing on
metabolic disorders. They specialize
in preclinical characterization of lead
molecules and demonstration of the
proof of their applicability to human
health. The company has pioneered
research of the hormone amylin and
is developing SYMLIN (pramlintide
acetate), a synthetic analog of human
amylin, for the treatment of diabetes
in people using insulin.

'70 30th Reunion June 10
Michael Ellis has contributed very
generously to Jefferson Medical
College to create a new scholarship, a
program which is vitally important to
the college. The Ellis family tradition
of giving to Jefferson has been
continued by Michael's son Jeffrey
Ellis '98 of Philadelphia.
Martin A. Tobey of Fort Worth, TX is
still practicing cardiology. He and his
wife, Judy, recently traveled to
Budapest, Prague, and Vienna on an
opera holiday.

'69
Jay S. Greenspan, M.D.,
4
Director of Jefferson's
Division of Neonatology,
was the featured speaker
at the recent Legacy
Society reception. He is
pictured with L. Roy
Newman '49 and Mrs.
Newman. The Legacy
Society recognizes
alumni and friends who
have generously supported Jefferson through bequests, life income gifts, or
other estate plans. The reception gave them the opportunity to talk with
President Paul C. Brucker, M.D. and other Jefferson leaders.
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Jay S. Skyler of Key Biscayne, FL has
been elected to the Board of Directors
of Amylin Pharmaceuticals,
headquartered in San Diego. Dr.
Skyler is Professor of Medicine,
Pediatrics, and Psychology and Codirector of the Behavioral Medicine
Research Center at the University of
Miami in Florida. He is also Director
of the Operations Coordinating
Center for the National Institute of
Diabetes and Digestive and Kidney
Disease's Diabetes Prevention Trial in
Type One Diabetes. Dr. Skyler has
served as President of the American
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'71
Paul M. Fernhoff of Atlanta, GA is
completing a sabbatical year at the
Centers for Disease Control working
on policies for newborn screening.

'74
David A. Brent of Pittsburgh, PA
continues as a Professor of Psychiatry
at the University of Pittsburgh,
directing a clinical research center
that treats depressed and suicidal
adolescents. "My greatest joy professionally," he says, "is helping young
people to succeed at research."

Genetics of Nicotine Addiction
May Explain Why It's Hard to Quit
or many people, even if they know
the health problems that smoking
causes, quitting is next to impossible.
And getting hooked in the first place
happened awfully fast. Of approximately 50 million smokers in the U.S.,
three fourths say they are addicted and
two thirds say they want to quit. After
surgery for lung cancer, nearly half of
those who survive resume smoking.
Among those whose
larynxes have been
removed, no fewer than
40 percent start smoking
again.

a trait and looking for genes in those
pairs that are present more frequently
than would be expected.

Philadelphia Medical Society Honors
Brady, Hughes, and Plotkin
Dr. Brady's interests also

he Philadelphia

include the arts. He serves

County Medical
"What predisposes you to certain

Society honored three

on numerous boards

behaviors is genetics. Some people
can smoke for years, and one day
decide to quit and never go back.
Others try and try and are never able
to stop. It may be too simplistic to say
that some people have
willpower and some don't.
We like to think of each
person as free-willed, but
the fact is much of our
behavior is wired.

Jeffersonians at its

including those of the

Awards Night in

Philadelphia Museum of

November 1999.

Art, the Santa Fe Opera
Foundation, and the

Luther W. Brady Jr. R'55
was recognized with the

Brady

gious prize of the evening. It is

Alumna Wins the Appel Award

given for overall contribution to

Tiffany A. Hughes '96, who
remained at Jefferson after

medicine or surgery.

Assistant Professor of

The reasons are many and complex.
An intriguing theory is that nicotine
addiction is due to a combination of
both environmental influences and
factors hardwired into the brain.
Some people may be genetically more
susceptible than others to become
addicted to the nicotine in cigarettes.
Dr. Leone is now using a clinical trial
to tease out the subtleties of nicotine
addiction, particularly the genetic
factors. He and his colleagues are
looking at 800 pairs of siblings who
smoke at least one pack of cigarettes a
day and are nicotine-dependent. Four
hundred pairs will be seen at Jefferson;
the others will be studied at several
other sites. Ashwin Patkar, M.D. of
Jefferson's Department of Psychiatry is
principal investigator.

"Despite similarities in
nicotine levels in the
blood, and in how people metabolize
nicotine, they differ in their
addictions," Leone says. He suspects
that the behavioral trait for nicotine
dependence may involve the genes
that control how we perceive and
process information.

Dr. Brady is known

year residency in internal

widely as a leader in

medicine, and is now a

radiation oncology and as

third year resident at

a scholar and patron of

Eastern Pennsylvania

the fine arts. He is

Psychiatric Institute, was

currently the Hylda

presented with the

Cohn/American Cancer

Hughes

Society Professor at the Medical

PCMS's Appel Award.
This is a monetary prize presented

College of Pennsylvania and

to a Philadelphia area psychiatric

Hahnemann University. Brady is

resident who submits the best paper

"There have been meaningful twin

the founder and Editor of

on clinical psychiatry

studies showing that identical twins
reared apart are more likely to both
smoke than fraternal twins reared
apart.

the American Journal of

relating to an experience

Clinical Oncology and a

in therapy or in research.

member of the editorial
Resident Wins the

boards of 11 journals.

C. Nelson Davis Award

Dr. Leone and his coworkers hope to
also conduct a study of unrelated
people who share the behavioral trait
to see if they share the same genes
more frequently than those without

society relating to his specialty,

the recipient of this year's C. Nelson

the trait.

and continues to be honored

Davis Award. This monetary prize is

internationally for his work. He has

presented for the best paper relating

"We might find that there are several
genes that interact with each other.
Genetics is additive.

"Once we know the genes, we could
figure out the biochemical pathway of
the addiction," Leone says.
The researchers are sampling genetic
material from each sibling. "If you share "Ultimately, we'd like to find a drug
a trait such as eye color, you're likely to that can inhibit the neural pathway
involved in the need to keep lighting
share genes that control them," Leone
says. "We're taking siblings who share
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Mexico.

Strittmatter Award, the most presti-

medical school for a one

Medicine Frank Leone
Leone
PUD'97 is trying to figure
out why some people can "go cold
turkey" on cigarettes and nicotine,
while others remain slaves to their
addiction.
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Randi L. Plotkin, M.D., a

Dr. Brady has been
president of nearly every

Plotkin

major professional

third year psychiatry
resident at Jefferson, is

participated in many committees of

to alcoholism or other addictive

the Philadelphia County Medical

disorders affecting physicians. Dr.

Society, including service as Chair

Plotkin's winning paper was

of the Center City Branch, Chair of

entitled "Counter Transference in

the Cancer Committee, and

Two Settings: A Case Report." It

Delegate to the Pennsylvania

focused on heroine abuse and

Medical Society.

addiction.4'
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She Can Be as Tough as Her Cases,
Though Not as High-profile
uestion: What do these people
have in common?
. John W. Hinckley Jr., attempted
assassin of President Reagan
. Jim Bakker, disgraced televangelist
. Theodore Kaczynski, the Unabomber
Answer: They all underwent psychiatric evaluation by Sally A. Johnson
'76, one of the nation's most respected
forensic psychiatrists. Johnson is
Chief of Psychiatric Services and
Associate Warden for Health Services
at the Federal Medical Center in
Butner, North Carolina. She teaches
at Duke University in both the Law
School and the School of Medicine, in
addition to being on the medical staff.
Defense lawyers said Kaczynski
suffered from paranoid schizophrenia
and had a phobia of being labeled
mentally ill. Prosecutors countered
that he was competent to stand trial.
Kaczynski, who attempted suicide
more than once and consistently
refused to be examined by
government psychiatrists, eventually
capitulated and underwent an
evaluation by Sally Johnson. He
hoped to be found competent to act as
his own trial attorney.
Johnson determined Kaczynski was
competent. Her report to the judge
linked Kaczynski's mental illness and
the Unabomb campaign. Consistent
with other individuals with
persecutory types of delusions, she
wrote, he was resentful and angry,
and fantasizes and actually does resort
to violence against those individuals
and organizations that he believes are
hurting him.
Sally Johnson's colleagues think her
skills are superb. John Monahan,
psychologist and law professor at the
University of Virginia, says, "There's
no question that the judge in the
Kaczynski case chose [a forensic
psychiatrist] well. Dr. Johnson is
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among the leading forensic
psychiatrists in the country.
She's known for her
thorough evaluations and
her balanced judgments.

clear by the nationally publicized
lawsuit over care at the new maximumsecurity facility in southern Illinois.)

If anybody is up to this
particularly challenging
evaluation, Dr. Johnson is."
And Walter Dellinger, a
former U.S. Solicitor General
and a professor at Duke Law
School, says he has known
few lawyers or physicians
who were able to combine
the necessary professional
detachment with the general sense of
humanity that he sees in Johnson.
"So many people who go into this
field are show people," says Dr. Keith
Brodie, former Chair of the Psychiatry
Department at Duke and former
President of Duke University. They're
flamboyant." But he calls Johnson
"very low-key, unflappable, not
pushy." Yet her evaluations make
page one of the New York Times.
Not surprisingly, Dr. Johnson
received the United States Attorney
General's Award for Distinguished
Service in July 1998 in Washington.
But while she obviously spends hours
asking endless questions of her
patients, she avoids answering
questions from the public. "She's very
intent about maintaining her professional integrity," her husband,
William Johnson, a lawyer and a vice
president of Carolina Power and
Light, told the Raleigh, North
Carolina News and Observer. She says
"no" to Ted Koppel, the famed TV
anchorman. "She never has given
interviews and probably never will.
And if I do, she will divorce me."
Johnson is a captain in the U.S. Public
Health Service assigned to the Federal
Bureau of Prisons. At Butner, she
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manages all medical services for 1000
inmates and serves as chief administrator for the 200-bed inpatient
psychiatric hospital on site. Butner is
one of three main psychiatry referral
centers for males in the federal prison
system.
While she was a student at Jefferson
Medical College, Johnson accepted a
public health scholarship, which
required two years of payback. She
took her residency at Duke University,
where she had brief experience with
prison populations. She scheduled her
Public Health Service work after
residency and chose the Bureau of
Prisons for payback.
"Clearly prisons are an area of need in
psychiatry," says Johnson, who refuses
Ted Koppel, but kindly consents to an
interview with the Alumni Bulletin.
(This need at prisons is surely made

"Prisons have a population of
individuals who are underserved,"
Johnson explains. "In a prison, you feel
you can make a difference. What I like
about the field has changed over time.
My interest in psychiatry has always
been in the treatment of psychosis. In
prisons, certainly, you have ample
opportunity to see psychosis. But more
importantly, you get to follow patients
over an extended time, which is
something you rarely get to do in the
general community. In prisons, you
come to understand the course of
illness, which is fascinating from a
clinical standpoint."
The difficulty, she says, is that there are
many treatment-resistant patients. One
challenge is trying to deliver health care
services in a system (prisons) where
health care is not the primary mission
"It's necessary (assuring that the health
care needs of prisoners are met), but it's
not the major focus." Over the last few
years, though, only part of Johnson's
work has been clinical. She consults
with prison systems around the country
on establishing training programs and
patient care programs.
The next time a high-profile, baffling
criminal is in the paper, look for Sally
Johnson's name as forensic
psychiatrist.

Editor's Note: We Are Providing You the Health Policy Newsletter
To keep Bulletin readers informed about Jefferson, while containing mail
costs, another publication is being shipped with the Bulletin. We believe
you'll find that the Health Policy Newsletter tells you about topics that
supplement those in the Bulletin. The Health Policy Newsletter is shipped
quarterly, and describes health policy questions that Jefferson is studying.
Please let us know your thoughts by directing them to
Attention: Editor, Alumni Bulletin
Jefferson Medical College
1020 Locust M-41
Phila., PA 19107
Phone: 215 955 7920 Fax: 215 923 9916
Email: Malcolm.Clendenin@maiLtju.edu

December 1 9 9 9

Do You Use E-mail?
Please tell the Alumni Office your e-mail address. It will be kept confidential,
and will only be used to inform you about Jefferson activities.
Simply send a message to jmc-alumni.office@mail.tju.edu

'77
Margaret M. Dunn has been
appointed Associate Dean for Faculty
and Clinical Affairs at Wright State
University School of Medicine,
effective September 1999.

Dr. Dunn is a Professor of Surgery at
Wright State. She also has served as
Associate Program Director of its
integrated surgical residency and Codirector of Surgical Education at
Miami Valley Hospital. Dr. Dunn
recently was elected President of the
American College of Surgeons, Ohio
Chapter, and is a past President of the
Association of Women Surgeons and
the Dayton Surgical Society. She is a
recipient of the Wright State
University Academy of Medicine's
Award for Excellence.

'80 20th Reunion June 10
Haynes "Tim" Cates Jr. of
Wilmington, DE has been appointed
Chief of the Division of Urology at
Christiana Care Health Care System
(the former Medical Center of
Delaware). This division of the
Department of Surgery at Christiana
has been on U.S. News and World
Report's "Best of list for the past
three years. Tim and his wife, Sally,
are the proud parents of Burke, 12,
and Kjell, 10.
Charles J. Dunton of Jefferson's
Kimmel Cancer Center answers
women's questions online about
gynecologic cancers in "Ask Our
Expert" on the Jefferson Health
System website (www.jeffersonhealth.org). Dr. Dunton is an
Associate Professor of Obstetrics and
Gynecology at Jefferson. The web
page enables browsers to ask Dunton
questions online, and receive an
online response within a week.
Jefferson's gynecology program was
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named this year by U.S. News and
World Report as among the best in the
country.

'84
Maureen D. Francis has joined the
faculty of Southern Illinois University
School of Medicine as an Assistant
Professor of Internal Medicine. She
comes from Boonville Family Practice
in Boonville, NC, where she was the
Medical Director. Previously she was
an Assistant Professor of Internal
Medicine at the Uniformed Services
University of Health Sciences in
Bethesda, MD.

'86
Melissa Moore Brown of Flourtown,
PA, was one of the featured speakers
for the annual commencement and
baccalaureate programs at Keuka
College, Keuka Park, NY, where she
is a member of the Class of '72. She
presently serves as a member of the
Keuka College Board of Trustees and
is President and CEO of the
Philadelphia Medical Press. In
addition to her ophthalmology
practice, she is cofounder of the
Pennsylvania Physician Healthcare
Plan.

'89

'92

John J. Walsh IV and Eugenia
Sarafidis Walsh are proud to
announce the birth of Benjamin
Christos, on June 23. Rita, age seven,
Joseph, five, and Gabriela, three, are
thrilled with their brother. John is
now a hand surgeon and Assistant
Professor of Orthopaedic Surgery at
the University of South Carolina
School of Medicine. Jenny returns to
her previous position as Assistant
Professor of Family and Preventive
Medicine in January 2000 after an
extended maternity leave. They live in
Columbia, SC.

Diane L Ching of Ambler, PA
is now a pediatrician at
Meadowbrook Pediatrics and Holy
Redeemer Hospital. She and Lynn
Silver Nugent have gotten together
a few times since both their
children happened to attend the
same preschool class last year.

'90 10th Reunion June 10
John A. Osborne of Collegeville, TX
has joined the staff at Baylor Medical
Center at Grapevine. Dr. Osborne's
specialty is cardiovascular physiology.
Mohan Suntharalingam of Baltimore,
MD was featured in the June issue of
the AAMC Reporter, a national
publication of the Association of
American Medical Colleges. The
article described "A Day in the Life of
a Junior Faculty Member." Dr. Suntha
is an Assistant Professor of Radiation
Oncology at the University of
Maryland.

'93
Dawn A. Demangone of
Philadelphia, PA married Dr.
Russell Yoon in October. Dawn is
now the Assistant Residency
Director in Emergency Medicine,
and Co-director of Medical Student
Education in Emergency Medicine
at Temple University.
Scott A. Rushton has joined the
Department of Orthopaedic
Surgery at the University of
Pennsylvania Health System. Dr.
Rushton specializes in complex
spine surgery and has published
several papers on the topic. He
completed his residency in
orthopaedic surgery at Jeff and
performed a fellowship in spine
surgery at University Hospitals of
Cleveland/Case Western Reserve
University.

'94
Scott Memorial Library privileges for medical college alumni including
postgraduate alumni: You may obtain a library card from the Scott Memorial
Library. On your first visit to the library, please present your blue plastic
alumni identification card and one form of photo identification (such as a
driver's license) at the circulation desk window located on the second floor of
the library. A barcode will be attached to your alumni ID card for no fee, and
you will be able to use it to borrow books and to avail yourself of many of the
services of the library free of charge.
Each time you visit the library, you will be required to show your alumni ID
card to the security officer stationed in the lobby. You may also be required to
produce photo identification. This is for the protection of the staff and patrons
of the library.
If you have misplaced your alumni ID card, you may call the JMC Alumni
Office (215 955 7750). After we have verified your status in the alumni
database, we will mail you an alumni ID card and a sheet listing the library
services available to alumni library card holders.
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Shmuel Shoham is currently living
in Brighton, MA and happily
married to Ruth Polk, a fellow in
infectious diseases at Boston
Medical Center. He is involved in
researching the immune response
to fungi.

'96
Matthew R. Panahandeh was
married in October 1998 to
Michelle Rathgeb, one of his fellow
residents in the Department of
Medicine at the University of
Pittsburgh. Jeffersonians in
attendance included Josephl
Murphy III, his best man, Stephen
D. Moy, Jason G. Wilmoth, Mark
A. Taylor, Jeff Namey, Brett Opel!,
and Stephanie L. Archer.

Nation's First Clinical Trial of Methods
to Treat Paralyzing Spinal Cord Injury
Julie Toms Poludniak of Elkton, MD
and husband, Tim, are proud to
announce the birth of their first
child, Sarah, born August 18.

'97
Charles P. McClure of Springfield,
PA is serving as Chief Resident in
Family Medicine at Bryn Mawr
Hospital for 1999-2000.

'99
Amami V. Gennanwala was one of
the senior medical students honored
at Jefferson in 1998-99 with Beach
Scholarships. He is now training in
orthopaedics at Penn State Geisinger
Health System in Hershey, PA.

Postgraduate Alumni
Yoogoo Kang AN'78 has been
appointed the Samuel Israel
Professor and Chair of
Anesthesiology at Tulane University
School of Medicine in New Orleans.
Dr. Kang is one of several
Jeffersonians recently appointed to
important posts in anesthesiology,
including Stephen E. Abram '70,
who is now Chair of Anesthesiology
at the University of New Mexico in
Albuquerque.
Dennis L. Priolo DR'88 has joined
the Landmark Medical Center in
Woonsocket, RI. Dr. Priolo is
certified by the American Board of
Radiology.
Maromi Nei N'99 has been
appointed a staff member of the
Comprehensive Epilepsy Center at
Jefferson, and Assistant Professor of
Neurology. Dr. Nei recently

completed a fellowship a the
center, which is one of the largest
epilepsy programs in the world and
is directed by Michael Sperling,
M.D. Dr. Nei is board certified in
psychiatry and neurology. She
completed a neurology residency at
the Hospital of the University of
Pennsylvania, where she received
the Samuel Zeritsky Clinical
Research Prize. Her research has
been published in journals
including Epilepsia and Neurology.
The staff of neurologists,
neurosurgeons, psychologists, and
neuroscientists at Jefferson's center
provide a wide array of services
including video EEG monitoring,
an internationally renowned
epilepsy surgery program, genetic
counseling, specialty care during
pregnancy, neuropsychological
evaluations, psychological care,
cognitive rehabilitation, social
support, and community education.

Graduate Studies
Clara M. Ambrus, Ph.D.'55 has
been elected to the Board of
Directors of Aethlon Medical,
headquartered in San Diego. The
inventor of the Hemopurifier line of
blood purification products, Dr.
Ambrus is the founder of Hemex,
Incorporated, a subsidiary of
Aethlon. A Research Professor of
Pharmacology, Pediatrics, and
Obstetrics-gynecology at SUNYBuffalo, she has expertise in
hematology, thrombosishemorrhage, respiratory distress
syndromes, and immobilized
enzymes. She has over 200
scientific publications to her credit.

Readers are encouraged to submit nominations for the Medical College
Alumni Achievement Award: The Achievement Award Committee of the
alumni association is charged with the final selection. Please direct curricula
vitae and bibliographies of medical college graduates, including postgraduate
alumni, whose professional activities are sufficiently outstanding to warrant
consideration to "Attention: Achievement Award Committee," 1020 Locust
Street M-41, Philadelphia, PA 19107.
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first-ever randomized study to
etermine the best therapy for
treating a paralyzing spinal cord injury,
began this fall at the Regional Spinal
- Cord Injury Center at Magee
Rehabilitation Hospital and Jefferson.

Magee, are placed in a parachute harness
and positioned over a treadmill. Once
the treadmill belt is moving, the investigation team, which includes physical
therapists, assist in moving the patient's
legs in a way that should optimize

Funded by the National Institute of
Child Health and Human Development,
the study will continue for five years.

sensory inputs. Clinical research has
shown that patients with certain types of
SCI who undergo this type of therapy
gain enhanced locomotor activity.

"Until now, there have been no scientific
studies to define which mode of therapy
works best for spinal cord injury,"

Dr. Saulino anticipates that approximately 25 patients will be enrolled

explains principal investigator John

annually. The Regional SCI Center is

Ditunno Jr., M.D., Director of the
Regional SCI Center.

one of five centers nationwide participating in the study.

Patients who have sustained an acute but
incomplete spinal cord injury will be
eligible for the study. Approximately half
of those who are treated at the Regional
SCI Center fall into this category.
Participants will be treated with either
conventional therapy which utilizes daily
mobility retraining, or a combination
of conventional interventions
and body weight-supported
ambulation therapy.

Jefferson, in affiliation with Magee, is
designated as one of the nation's 18
Regional Research Spinal Cord Injury
Centers, and the only one in the

"We want to determine which

named this year by U.S.
News and World Report in
its "America's Best
Hospitals" issue as among
the foremost rehabilitation
programs in the
nation—the only
Philadelphia providers to achieve
this honor.

type of therapy produces
better ambulation status or
walking ability," says Michael
Saulino PM'97, Instructor in

Rehabilitation Medicine and
Saulino
Assistant Director of Resident
Education, "and whether motor skills
are improved."
The theoretical basis of body weightsupported therapy is the concept of a
central pattern generator. "This is based
on a belief that the human spinal cord
has an intelligence all its own that can
generate steplike electrical patterns when
exposed to sensations like walking,"
Ditunno explains.
Patients must have sustained their spinal
cord injury within eight weeks of taking
part in the study, and have some feeling
or movement below the position of the
injury. Subjects undergoing the weightsupported ambulation, which is done at

December 1999

Delaware Valley. It is also federally
designated as a Model System SCI
Center.
Jefferson and Magee, along
with MossRehab—all
members of the Jefferson
Health System—were

The Regional SCI Center, which has
treated more than 2,500 individuals,
provides a multidisciplinary system of
acute care and rehabilitation. It offers
services from the moment of injury,
through acute and rehabilitation phases,
to followup care and reintegration into
the community. With over 70 percent of
persons with SCI admitted within three
days of injury, the center has
demonstrated a mortality rate of five
percent (as compared to a 17 percent
national average) and has significantly
reduced the severe secondary
complications.
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